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ABSTRACT 
 
 
In recent years, a small diatomic free radical gas molecule known as nitric oxide (NO) has gained 
much attention by the biomedical community due to its potential use as a therapeutic agent.  In 
this dissertation, a NO donor (S-Nitrosoglutathione (GSNO)) is incorporated into newly devised 
NO releasing topical creams to potentially treat wound or skin infections, and within novel NO 
releasing insert devices for disinfecting the hub region of tunnel dialysis catheters (TDCs).  GSNO 
is used throughout this research because it is an endogenous carrier of NO in the human body and 
is therefore likely to be non-toxic for potential biomedical applications. 
In Chapter 2, GSNO is shown to be stabilized when mixed in Vaseline and stored under dry 
conditions for 300+ days.  Also, it is demonstrated that a commercial ZnO-containing cream, when 
combined with the GSNO in Vaseline mixture, enhances the NO release rate from GSNO.  In 
Chapter 3, the antimicrobial effects of the NO releasing creams are shown to exhibit significant 
antimicrobial activity versus S. aureus, S. epidermidis, and P. aeruginosa.  A NO releasing cream 
modified by the addition of NaHCO3 to achieve a neutral pH cream also exhibits similar 
antimicrobial effects. 
In Chapter 4, solution phase studies reveal that ZnO is the primary component responsible in the 
commercial ZnO cream for the enhanced NO release rate from GSNO.  Further studies show that 
30 nm size ZnO nanoparticles increase NO release rate by a factor of 2.78 compared to no ZnO 
present.  Surface analysis of ZnO suggests no evidence of Zn-S bond formation or thiol attachment 
after interaction with GSNO. 
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In Chapter 5, a NO releasing insert device is introduced as an innovative method to disinfect the 
hub region of TDCs.  A short-term shelf-life stability study shows minimal GSNO degradation 
within the insert device after 56 d of dry/dark storage after H2O2 sterilization.  Once wetted up by 
soaking in saline solution, the NO releasing insert device exhibits significant antimicrobial effects 
against S. aureus and P. aeruginosa present in the liquid of catheter hubs.  Two 14 d long sheep 
studies demonstrate that the NO releasing insert device is exceptionally potent at preventing 
bacteria/biofilm growth on the inner lumen walls of the catheters compared normal caps and a 
chlorhexidine cap. 
Significant achievements showcased in this thesis include creation of potent antimicrobial NO 
releasing creams, discovery of increased NO release from GSNO using ZnO nanoparticles, and 
creation of NO releasing insert devices capable of preventing bacteria and biofilm growth in 
catheters.  The NO releasing creams provide an attractive alternative method to antibiotic creams 
to treat dermal infections.  The NO releasing insert devices have the potential to significantly lower 
the number of infections caused by TDCs and other intravascular catheters. 
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Chapter 1 Introduction 
 
 
1.1 Antiseptic Agents 
1.1.1 Purpose and function of antiseptics 
Throughout history, dermal wound infections have been quite prevalent.  Primitive treatments 
include substances from animals, plants, and minerals.1  Some of these earliest primitive treatments 
would now be classified as antiseptic agents.  The first recorded use of an antiseptic agent was by 
Dr. Joseph Lister in 1867.2  Using carbolic acid to sterilize his surgery tools, instruments, and 
wound bandages, significantly lowered the number of deaths after surgery due to infection.  Since 
that time, several other antiseptic agents have been utilized for their antimicrobial properties.  
Some antiseptics that have been widely utilized include chlorhexidine, silver compounds (silver 
nitrate or silver nanoparticles), iodine compounds (cadexomer or povidone-iodine), and honey to 
name a few.  Their antimicrobial functions vary immensely. For instance, chlorhexidine decreases 
cell wall integrity by binding to the negatively charged groups located on the outside of bacteria 
cells.3, 4  Silver ions can also bind to the negatively charged groups present on the cell membrane 
causing denaturation of the cell membrane.5  Silver nanoparticles can readily penetrate cell walls 
and produce intracellular reactive oxygen species (ROSs). These ROSs can damage DNA, RNA, 
lipids, and proteins leading to apoptosis.6  Iodine-containing compounds such as cadexomer and 
povidone-iodine function by delivering iodine to the cell surface.  Iodine can easily penetrate cell 
walls and bind to proteins, nucleotides, and fatty acids present in the cell wall or cytoplasm.7  Lastly 
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honey, arguably one of the oldest traditional medicines, inhibits bacteria growth by its inherent 
low pH, high osmolarity (high sugar content), and production of hydrogen peroxide.8  Hence, as 
described by the selected examples above, antiseptics can demonstrate various 
functions/mechanisms by which killing or inhibition of bacteria growth is carried out. 
 
1.1.2 Antiseptics used for topical treatments 
An antiseptic that has remained the dominant biocide in the prevention of infections is 
chlorhexidine.7  The most common form of chlorhexidine used in clinical settings is chlorhexidine 
gluconate (water-soluble).4, 9 Chlorhexidine has been incorporated into many products such as 
shampoos, eye creams, hand creams, and sunblocks.9  Chlorhexidine is a broad-spectrum 
antimicrobial agent, but it is most effective against gram-positive bacteria.10-13  As  stated above, 
chlorhexidine’s mechanism of action against bacteria involves binding to negatively charged 
moieties present on bacteria cell walls/membranes, which leads to instability and cell death.3, 4  
Kramer et al. demonstrated the antimicrobial effects of a commercially available cream containing 
chlorhexidine against Enterococcus hirae and Candida albicans.14  After 10 min of exposure to 
the chlorhexidine cream during a standard quantitative suspension test with simulated wound bio-
burden, >3 log unit reduction was observed in the number of live E. hirae and C. albicans cell 
counts.14  To date numerous reports have been published on the impressive, fast killing capabilities 
of chlorhexidine in preventing and fighting infections. 
Another antiseptic agent that is commonly used is iodine.  The antiseptic properties of iodine were 
discovered in the early 1800s and have been utilized ever since.15  The most common form of 
iodine is called povidone-iodine, which consists of complexed iodine and poly(vinylpyrrolidone).7, 
15  Povidone-iodine arguably has the broadest spectrum of activity of any antiseptic, with reports 
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of activity against a vast range of fungi and bacteria, including Pseudomonas, Staphylococcus, 
Mycobacterium, Candida, and Trichophyton species.3, 16  Hill et al. showed the antimicrobial 
capabilities of a 5% povidone-iodine cream at killing methicillin-resistant Staphylococcus aureus 
(MRSA).17  Upon direct inoculation of the 5% povidone-iodine cream with various strains 
including three MRSA types (separately), all strains were killed after 30 s of exposure, leading to 
a killing rate of ~104 CFU/s.17  This report clearly demonstrated the potent antimicrobial nature of 
povidone-iodine. 
 
1.1.3 Limitations and downfalls of antiseptics  
In general, antiseptics are effective at killing both gram-positive and gram-negative bacteria 
strains.  The degree to which the antiseptic is effective is typically concentration dependent.  
However, increasing the concentration of an antiseptic can have cytotoxic effects.  For example, 
there have been cases of chlorhexidine causing anaphylaxis to occur.18, 19  Additionally, 
chlorhexidine has trouble dispersing and killing bacteria within biofilms, and this is a concern for 
treating tissues/areas that are already infected.20  One mechanism of resistance that has been 
reported for chlorhexidine is the presence of efflux pumps.  Efflux pumps are protein complexes 
capable of removing chlorhexidine from the cell.21  Efflux pumps are usually found in gram-
positive Staphylococci bacteria.22  Prag et al. observed a chlorhexidine tolerance of 37.5% towards 
143 Staphylococcus epidermidis isolates, collected from a hospital.23  Overall, however, 
chlorhexidine has many positive benefits with only minor/few downfalls or limitations. 
Povidone-iodine has been used for a wide variety of clinical applications, with no reports of fungi 
or bacteria resistance or increased tolerance to this agent.7, 24  However, in several clinical 
applications, povidone-iodine has been replaced with chlorhexidine because of chlorhexidine’s 
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more prolonged/lingering activity.25  There are some reports of contact dermatitis and skin 
irritation after prolonged contact with povidone-iodine but these are considered to be rare.26-28  
Overall, povidone-iodine has withstood the test of time and has proven itself as an effective broad-
spectrum antimicrobial agent with few downfalls or limitations. 
 
1.2 Antibiotics 
1.2.1 Purpose and function of antibiotics 
When it became generally accepted that micro-organisms were the cause of infection, the door for 
scientists to develop chemicals/medicine with specific targeting capabilities was opened.  This led 
to the rapid development of a class of antimicrobials known as antibiotics.  During the 19 th and 
20th centuries, hundreds of antibiotics were developed with the purpose to destroy or inhibit the 
growth of vulnerable bacteria by various means.29  In general, antibiotics are nontoxic, making 
them ideal for human use.30  Most antibiotics can be classified into 6 groups: penicillins, 
cephalosporins, aminoglycosides, tetracyclines, macrolides, and fluoroquinolones. The function 
by which these types of antibiotics kill or inhibit bacteria growth varies depending the antibiotic 
itself and upon bacteria type (gram-positive or negative, aerobic or anaerobic).  For example, 
penicillin-based antibiotics function by affecting the structural integrity of the bacteria’s cell wall.  
Specifically, they block protein struts that cross-link peptidoglycans, which are essential for 
building a protective layer around the plasma membrane of bacteria cells.31  Inhibition of 
peptidoglycans indirectly causes the rupture of the cell wall by allowing foreign material/fluid to 
enter the cell through tiny holes causing the cell to burst from the excess pressure.32  Gram-positive 
bacteria contain higher levels of peptidoglycan compared to gram-negative organisms.31, 32  
Therefore, penicillin-based antibiotics are most effective against gram-positive bacteria strains.   
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Another general antibiotic group called the aminoglycosides function in a different manner to kill 
and inhibit bacterial growth.  Aminoglycoside-based antibiotics are known to inhibit bacteria 
protein synthesis by binding to specific ribosomal subunits present in the intercellular fluid.31  This 
causes misreading of mRNA and synthesis of atypical peptides, which leads to errors in protein 
synthesis and cause cell death.33  Reports demonstrate that aminoglycosides are mostly effective 
against aerobic, gram-negative bacteria because their crossing of the bacteria cell membrane 
depends on the aerobic metabolism.31, 33  The above examples demonstrate how certain antibiotics 
function.  In general, antibiotics are highly selective towards specific strains and types of bacteria 
due to their inherent bactericidal function. 
 
1.2.2 Antibiotics in ointments, creams, and hydrogels 
One use of antibiotics is within ointments, creams, and hydrogels for topical antimicrobial 
applications due to their efficacy and low toxicity.  Utilized since 1956 and approved by the U.S. 
Food and Drug Administration (FDA) in 1971, the most common nonprescription triple-antibiotic 
ointment (TAO) (<20% water content) contains a combination of neomycin, polymyxin B, and 
bacitracin.34-36  The triple antibiotic combination is utilized because of the limited spectrum each 
has individually.  Neomycin is an aminoglycoside antibiotic effective mainly against aerobic gram-
negative organisms while excluding most Pseudomonas species.31, 34  Polymycin B is effective 
against some gram-negative strains, including Pseudomonas species.31, 34  Bacitracin is most 
effective against gram-positive strains.31, 34  This TAO has been evaluated and studied extensively 
over many decades and has become the standard antimicrobial topical ointment.  A clinical study 
performed from 1989-1990 demonstrated how effective TAO can be at preventing infections of 
soft-tissue wounds repaired in a hospital emergency department.37  This study compared TAO, 
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bacitracin zinc ointment (BAC), silver sulfadiazine cream (SIL), and petrolatum (PTR) (control) 
applied three times a day to the wound site.  Upon study completion, use of TAO resulted in 
significantly lower infection rates compared to the PTR control: 4.5% and 17.6%, respectively 
(BAC=5.5%, SIL=12.1%) (n=106.5 patients each treatment).  TAO had the lowest infection 
percentage of all evaluated treatments, labeling it as a safe way to prevent infection of wounds that 
require closure.  This is just one of many studies involving the antimicrobial efficacy of TAO. 
For a topical treatment to be considered a cream, the amount of water must be >50%.  One example 
of  a commonly used antibiotic-containing cream is 0.1% gentamicin cream.30  Gentamicin is a 
broad spectrum antibiotic, effective against a number of gram-positive and gram-negative 
strains.30, 38  Several studies report using 0.1% gentamicin cream to treat/prevent exit-site 
infections (ESIs) from peritoneal dialysis catheters.38-42  In these reports, the treatment of ESIs 
using the gentamicin cream was mainly compared to a mupirocin cream/ointment (another 
common topical treatment for ESIs).  Mupirocin is an antibiotic mainly effective against gram-
positive bacteria strains and therefore highly effective at reducing ESIs caused by S. aureus.43, 44  
Reports that compared these two topical treatments, collectively showed that the gentamicin cream 
was able to match or exceed the reduction of ESIs compared to the mupirocin cream/ointment.  In 
particular, Bernardini et al. showed that ESI rates were 0.23/yr using a gentamicin cream and 
0.54/yr using a mupirocin cream.40  Interestingly, there were no P. aeruginosa (gram-negative 
bacteria strain) ESIs when using the gentamicin cream compared to a 0.11/yr ESI rate using the 
mupirocin cream because mupirocin is not a broad-spectrum antibiotic. 
Hydrogels have also been used in combination with antibiotics for various topical applications.  
Hydrogels are 3D porous materials synthesized using water-soluble polymers that can turn into a 
gel under defined conditions (temperature, pH, ultraviolet exposure, enzyme catalyst, etc.).45-47  
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Some advantages to using a hydrogel include protection of the antibiotic(s), controlled release, 
high surface area to volume ratio, and controlled porosity to increase biocompatibility with natural 
tissues.45, 46  Ciprofloxacin is a popular antibiotic incorporated into a hydrogel because of its broad-
spectrum antimicrobial activity against gram-positive and gram-negative bacteria strains.48-55  
Zhou et al. demonstrated that ciprofloxacin incorporated into a poly(vinyl alcohol) 
(PVA)/poly(ethylene glycol) (PEG) porous scaffold hydrogel was able to completely inhibit the 
growth of E. coli in solution compared to a PVA/PEG control.55  Marchesan et al. reported the 
antimicrobial capabilities of a ciprofloxacin self-assembled with a tripeptide (DLeu–Phe–Phe) to 
yield a hydrogel after a pH trigger.49  A qualitative micro gel well diffusion assay was performed 
against S. aureus (gram-positive), E. coli (gram-negative), and K. pneumoniae (gram-negative) 
(Fig. 1.1).  An inhibition zone was seen for all ciprofloxacin-loaded hydrogels, demonstrating the 
broad-spectrum antimicrobial effects of ciprofloxacin. 
 
Figure 1.1. Antibacterial efficacy of 0.2% w/v ciprofloxacin (CIP) tripeptide gel and controls of 
only tripeptide gel against S. aureus, E. coli, and K. pneumoniae agar layer cultures.  Images taken 
after 20 h of incubation at 37°C.49 
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1.2.3 Limitations and downfalls of antibiotics for topical treatments 
One user-convenience that the triple-antibiotic ointment (TAO) lacks is spreadability, especially 
over large areas of skin, because it is inherently an ointment (<20% water).  To increase 
spreadability, manufacturers increased the water percentage to >50%, classifying it as a cream.  
Unfortunately, bacitracin is not stable over long periods of time in an aqueous environment.36  
Therefore, bacitracin was removed from the cream formulation, leaving only neomycin and 
polymyxin B.  Removal of bacitracin lowers the effectiveness of the new cream with only 
neomycin and polymyxin B against gram-positive strains.  This is an example that demonstrates 
how a major limitation of using antibiotics is their specificity towards specific bacteria 
types/strains. 
As mentioned previously, gentamicin- or mupirocin-containing creams are commonly used for 
treating/preventing exit-site infections (ESI) from peritoneal dialysis catheters.38-44  However, a 
limitation of using the mupirocin cream/ointment is its lack of broad-spectrum activity, especially 
towards gram-negative bacteria such as P. aeruginosa.40  Even though gentamicin is a broad-
spectrum antibiotic, occurrence of ESIs when using a gentamicin cream have been linked to its 
lengthy broad-spectrum suppression of indigenous skin flora, causing atypical organisms to 
grow.39  Another study aimed to avoid this prolonged broad-spectrum suppression by 
interchanging applications of gentamicin cream and mupirocin cream.  However, there was no 
change in ESI rate compared to just using the gentamicin cream.38  Instead, the alternating 
application regimen caused a higher incidence of antibiotic-related fungal peritonitis.38  These 
examples demonstrate how even broad-spectrum antibiotics have downfalls. 
In general, antibiotics are nontoxic to humans.  However, some antibiotics display toxic behavior 
depending upon their concentration.  For example, ciprofloxacin-loaded hydrogels (mentioned 
 9 
earlier) have a history of toxicity related to dosage/concentration of ciprofloxacin.46  Du et al. 
demonstrated the cytotoxicity of ciprofloxacin-loaded nano-in-micro hydrogel particles on RAW 
macrophage cells.56  Versus a control of ciprofloxacin-free hydrogel particles, the viability of the 
RAW macrophage cells was reduced by 38.4% after 24 h of exposure at 37°C for the lowest 
concentration of ciprofloxacin tested (320 µg/mL).56  This example demonstrates how some 
antimicrobials have cytotoxic effects even though the vast majority of antibiotics are deemed 
nontoxic. 
 
1.3 Nitric Oxide 
1.3.1 Purpose, function, and properties of nitric oxide 
Over the past three decades, a small gaseous molecule, nitric oxide (NO), has gained much 
attention due to its potential as a therapeutic agent.  In the 1980s, NO was discovered to be the 
endothelium-derived relaxing factor (EDRF) that causes relaxation of smooth muscle cells located 
in blood vessel walls.57  This effect causes vasodilation, increasing blood flow to body tissues, and 
lowers blood pressure.  NO is synthesized from L-arginine in vivo via three nitric oxide synthase 
(NOS) enzymes.57  In the presence of molecular oxygen, L-arginine is oxidized to NO and L-
citrulline.  Two of these NOS enzymes, neuronal NOS (nNOS) and endothelial NOS (eNOS), are 
permanently active and play key roles in biological functions such as neurotransmission and 
prevention of platelet activation and aggregation.57, 58  However, induced NOS (iNOS) is active 
only when the body undergoes an immune response to foreign species (proteins, bacteria, viruses, 
etc.).57, 59  The half-life of NO in blood is short, 0.5-1.0 s, because it is highly reactive and is 
quickly scavenged by oxyhemoglobin (to form methemoglobin).57, 58  NO also reacts with thiols 
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(RSHs) to form S-nitrosothiols (RSNOs), and can thereby be stored and transported to target 
locations within the body.60 
Nitric oxide is highly reactive because it is a diatomic free radical molecule.  Therefore, NO is a 
potent broad-spectrum antimicrobial agent because it can cause multiple reactions that lead to 
bacteria cell death.58, 61  The two main mechanisms by which NO can cause cell death are via 
nitrosative and oxidative stress (Fig 1.2).61  Nitrosative stress occurs by NO reacting with 
molecular oxygen to yield NO2 radical.  This species reacts with another NO to yield the reactive 
product N2O3.  N2O3 then reacts with thiol groups (RSH) present on the surface proteins of bacteria, 
causing the cell wall to denature and break apart, killing the bacteria cell.  Oxidative stress occurs 
when NO is present in the intracellular fluid of the bacteria cell.  NO is highly lipophilic and 
therefore can readily pass through bacteria cell walls/membranes.62  Once inside, NO reacts with 
superoxide (derived from cellular respiration) to form peroxynitrite (ONOO-).  Peroxynitrite 
triggers lipid peroxidation reactions to occur, which causes cell membrane destruction. 
 
Figure 1.2. Mechanisms by which NO acts as an antibacterial agent.61 
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NO not only displays antimicrobial effects against a broad range of bacteria, it is also effective 
against viruses, fungi, and yeast.63, 64  NO also displays great dispersal/displacing activity against 
microbial biofilms.65-68  One example of NO’s anti-biofilm effects was demonstrated by Wo et al., 
where the authors achieved a 5 log unit reduction in S. aureus cell counts between a NO releasing 
catheters versus a control catheters when placed within a 7 d drip-flow bioreactor under 
physiological conditions.68  Overall, NO’s many unique properties make it an attractive and potent 
antimicrobial/anti-biofilm agent.  
 
1.3.2 NO releasing agents for topical treatments 
NO is synthesized in skin tissue by fibroblasts, keratinocytes, melanocytes, and Langerhans 
cells.57, 69  On the skin surface, NO is produced via chemical and bacterial reduction of sweat 
nitrate.69  In recent years, the application of NO for the treatment of dermal conditions has been 
explored as it has several attractive properties, such as being a potent antimicrobial and anti-
inflammatory agent, as well as increasing angiogenesis, i.e. proliferation of new blood vessels (for 
potential wound healing applications).  Various NO donor platforms and methods have been 
investigated with the goal to develop systems capable of delivering/releasing NO in a controlled 
and efficient manner.   
S-Nitrosothiols (RSNOs) are a class of NO donor molecules that have immense therapeutic 
potential because of their inherent low toxicity and ability to store and release NO (Fig. 1.3).70  
However, RSNOs are fairly reactive and can release NO in the presence of reducing agents, metal 
ions (e.g. Cu(I/II)), as well as by thermal degradation and photolysis.71-78  Therefore, incorporating 
RSNOs into various topical matrices may increase their stability. 
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Figure 1.3. Structures of various RSNOs. 
 
Oliviera et al. studied the effect of incorporating GSNO and SNAC into a hydrogel comprised of 
Pluronic F127, a triblock copolymer of poly(ethylene oxide)—poly(propylene oxide)—
poly(ethylene oxide).79  Thermal and photochemical NO-release rates from S-nitrosoglutathione 
(GSNO) and S-nitroso-N-acetylcysteine (SNAC) in water and the hydrogel were determined.  
Comparing GSNO incorporated within the hydrogel to GSNO incorporated within water, the NO-
release rate decreased 2.0-fold at 37°C and 1.5-fold when irradiated at >480 nm (Fig. 1.4).79  The 
Pluronic F127 hydrogel has the unique property of reverse thermal gelation, and this stabilizes the 
RSNO by a cage recombination effect.  The geminate radical pair that forms from the hemolytic 
cleavage of the S—N bond is more likely to undergo radical pair recombination in the solvent 
cage, thus reducing the decomposition of RSNOs and prolonging the NO-release to approximately 
2 h.79   
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Figure 1.4. Real-time NO release from GSNO incorporated into (a) hydrogel-dark, (b) H2O-dark, 
(c) hydrogel-irradiated, (d) H2O-irradiated; irradiated with λ > 480 nm.79 
 
Other literature reports have demonstrated how incorporating GSNO into a hydrogel increased 
blood flow when applied to human skin and improved and accelerated the wound healing process 
of rat models.80-85  For example, Georgii et al. showed that application of a hydrogel containing 
GSNO to an ischemic wound versus a control hydrogel, increased the wound closure rate.  The 
faster wound closure was attributed to NO’s antimicrobial, anti-inflammatory, and pro-
angiogenesis properties. 
Another class of NO-donor molecules that have been extensively studied are diazeniumdiolates.  
One advantageous property of diazeniumdiolates is that they release two moles of NO per mole of 
NO donor via acid catalyzed spontaneous decomposition.86  A potential issue with using 
diazeniumdiolates as a NO-donor is the possibility of N-nitrosamine formation, and most 
nitrosamines are carcinogenic.87, 88  Nonetheless, various NO releasing diazeniumdiolate scaffolds 
have been studied for their potential therapeutic purposes because they can store and release large 
payloads of NO.  For example, N-diazeniumdiolate-functionalized dendrimers have been 
examined thoroughly and the NO release rates can be tuned based on the number of terminated 
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primary amines.  Stasko et al. determined that the NO release half-lives under physiological 
conditions of dendrimer polypropylenimine with 16 or 64 terminated primary amines were 12 and 
29 min, respectively.89  The slowed decomposition rate of the larger dendrimer was attributed to 
the abundance of neighboring amine sites.  The neighboring amines sites provide alternative sites 
of protonation, which slows the proton driven dissociation of diazeniumdiolates.90  Similar 
diazeniumdiolate-modified dendrimers were tested on Streptococcus mutans for biofilm 
disruption.91  The bactericidal and anti-biofilm activity was increased for the NO-releasing 
dendrimers with greater exterior hydrophobicity.  Also, the faster NO-release kinetics yielded 
greater bactericidal activity compared to slow NO-release dendrimers.  However, higher 
concentrations of diazeniumdiolate-modified dendrimer lead to greater toxicity to mammalian 
cells, reducing cell viability by up to 70%.  The authors attributed the inherent toxicity to the large 
dose of NO.91   
NO-releasing silica nanoparticles modified with diazeniumdiolate NO donors have also been 
investigated.  Instead of functionalizing just the outside of the silica nanoparticles like for the 
modified dendrimers, Hetrick et al. developed a synthetic scheme that allowed NO moieties to be 
present on the surface as well as within the pores of the silica nanoparticles.61  This new method 
involves forming the diazeniumdiolate on the silane’s secondary amine before performing a 
condensation reaction with tetraalkoxysilane to synthesize the NO-releasing silica nanoparticle.  
This unique structure allowed for the storage of larger NO payloads.  When tested against P. 
aeruginosa, the NO releasing silica nanoparticle provide a 3 log unit reduction in cell counts with 
within 90 mins of exposure under physiological conditions. 
A company called Novan Therapeutics Inc. is using a version of these NO releasing silica 
nanoparticles within a type of hydrogel for topical treatments.  The company’s product at various 
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concentrations has shown promising antimicrobial effects against methicillin-resistant 
Staphylococcus aureus (MRSA) (Fig. 1.5). 
 
Figure 1.5. MRSA bacteria counts after being untreated, being treated with just the vehicle 
hydrogel, and being treated with 2, 6, or 12% concentration of Novan’s product on various days 
(graph taken from novan.com). 
 
1.4 Summary 
Antiseptic agents have long been utilized by the biomedical field for their broad-spectrum 
antimicrobial effects.  Unfortunately, given antiseptics are not always suitable/safe for all 
applications.  The discovery and development of antibiotics brought the medical community an 
effective/nontoxic way to target specific bacteria strains/infections.  However, the evolution of 
antibiotic resistant bacteria strains has severely reduced the effectiveness of antibiotics.  This 
phenomenon has made development of new antimicrobial agents/techniques a hot topic in the 
biomedical field.  Overall, NO’s potential to be used for various biomedical applications is quite 
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high.  NO’s many advantageous properties has driven researchers to utilize NO for several 
antimicrobial applications including topical treatments. 
 
1.5 Statement of Thesis Research 
The purpose of this dissertation is to examine the characteristics and antimicrobial capabilities of 
newly devised NO releasing creams and devices.  Moreover, this research introduces a novel 
method for releasing NO from S-nitrosoglutathione (GSNO) using zinc oxide (ZnO) nanoparticles.  
There is a heavy focus on using GSNO as the NO donor because it is endogenously produced and 
therefore relatively non-toxic.  Furthermore, the stability of GSNO is a primary topic addressed in 
several chapters.  Each NO releasing project has considerable practical application, with the goal 
of preventing/treating infections in the biomedical field. 
 
Chapter 2 analyzes the characteristics and capabilities of various NO releasing two-part cream 
formulations.  This includes evaluating the long-term storage capabilities of GSNO within a 
hydrophobic matrix, namely Vaseline.  Also, the NO release kinetics from GSNO stored in 
Vaseline when combined with a commercial ZnO-containing cream are reported.  The NO release 
properties of this mixture are shown to be promising for potential antimicrobial applications.  
 
Chapter 3 evaluates the antimicrobial effects of the NO releasing two-part creams developed in 
Chapter 2.  Indirect and direct application studies of the NO releasing creams onto different 
bacteria strains cultured on agar plates and also on pig skins were performed.  Very significant 
antimicrobial activities for all bacteria tested are reported.  Experiments to assess the antimicrobial 
activity of the NO releasing creams with various pH’s were also conducted. 
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Chapter 4 investigates the NO release from GSNO in the presence of ZnO nanoparticles.  ZnO was 
proved to be substance responsible within the commercial ZnO cream that enhances NO release 
from GSNO.  Solution phase studies were performed with GSNO and ZnO nanoparticles of 
different diameters to gain insight into how enhanced NO release from GSNO occurs in the 
presence of such particles. 
 
Chapter 5 introduces a NO releasing insert device to disinfect the hub region of tunnel dialysis 
catheters (TDC).  The NO release characteristics of various GSNO/ZnO-containing inserts were 
evaluated, along with their antimicrobial capabilities.  Sheep studies evaluated the performance of 
the NO releasing insert device against normal TDC caps and a commercially available 
antimicrobial cap. 
 
Finally, Chapter 6 provides a summary of the major conclusions drawn from the research described 
in Chapters 2-5. In addition, this chapter details suggestions for future experiments that can expand 
on the existing knowledge for the new GSNO-ZnO based NO release chemistry discovered via the 
research described in this dissertation. 
 
The research reported herein consists of studying novel NO releasing creams/devices for various 
biomedical applications.  The NO releasing creams utilizing GSNO, Vaseline, and ZnO cream 
display significant antimicrobial effects on three bacteria strains associated with dermal or wound 
infections.  These NO releasing creams have the potential to be a better alternative to using existing 
antibiotic-containing creams for dermal or wound infections.  It was discovered that ZnO 
nanoparticles can enhance the NO release rate from GSNO.  This discovery can potentially impact 
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future research studies to incorporate ZnO nanoparticles to increase NO release from GSNO or 
other RSNO species.  The NO releasing insert device is shown to exhibit significant 
antimicrobial/anti-biofilm effects when used with tunneled dialysis catheters.  This NO releasing 
insert device could significantly lower the number of catheter related infections for hemodialysis 
patients. 
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Chapter 2 Development and Characterization of Nitric Oxide Releasing Two-Part Creams 
 
Reprinted from Nitric Oxide, Vol. 90, Nitric oxide releasing two-part creams containing S-
nitrosoglutathione and zinc oxide for potential topical antimicrobial applications, Doverspike, J. 
C.; Zhou, Y.; Wu, J.; Tan, X.; Xi, C.; Meyerhoff, M. E. Copyright 2019, with permission from 
Elsevier. 
 
2.1 Introduction 
Infected wounds can lead to serious issues such as delayed wound healing, necrosis, limb or life-
threatening situations, and spread of infection not only in the patient’s body but to others in a 
hospital setting.1-3  The most common topical treatments to prevent or treat infections often utilize 
antibiotics.4 Consequently, the effects of these treatments over time diminish as multi-drug 
resistant bacterial strains continue to evolve.5-7 Over the past decade, the rate of antibiotic 
resistance has increased rapidly, caused by the misuse of antibacterial agents.6, 8, 9 Organizations 
such as the World Health Organization (WHO) and Centers for Disease Control and Prevention 
(CDC) have declared antibiotic resistance as a global health concern.8, 9 
When considering topical antimicrobial treatments, either prescription or non-prescription type, 
the treatment must display several characteristics to be an effective agent.  First, active ingredients 
must be safe and stable.  According to U.S. Food and Drug Administration (FDA) standards, new 
cosmetics with drugs must report an extensive amount of safety data that also demonstrate stability 
of the ingredients.10, 11 Topical antimicrobial treatments fall within this category.  Second, the 
active components (e.g., antibacterial agent(s)) should exhibit activity towards a wide range of 
microbes (non-selective).6 This will ensure broad application potential of the antimicrobial 
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treatment. Third, the treatment must be practical and effective over a designated application period.  
For example, treatments that would require application every 30 minutes would be considered 
impractical; however topical application once or twice daily would be much more acceptable.   
An example of an antimicrobial treatment that is capable of meeting all of the above criteria is one 
that incorporates nitric oxide (NO) as an active ingredient.3, 12-18  Nitric oxide (NO) is a simple 
diatomic free radical that has drawn much attention in the biomedical field due to its potential as 
a therapeutic agent.14, 19, 20  NO is naturally synthesized in vivo by the enzyme nitric oxide synthase 
(NOS) and plays a key role in several biological functions such as neurotransmission, prevention 
of platelet activation and adhesion, and serving as a potent antimicrobial/antiviral agent produced 
by immune system macrophages to fight infection.21-24 As a free radical, NO can facilitate a 
multitude of reactions leading to microbial cell death, making it ideal for therapeutic 
applications.14, 19, 25  To date, NO has displayed broad activity, killing many different types of 
bacteria.14, 25 
Free radical molecules like NO are highly reactive and therefore NO donor molecules are often 
utilized to stabilize NO, and then release NO locally upon demand.  Some NO donors that have 
been used for antimicrobial/wound healing applications include nitrite (converted to NO by 
reduction reaction), N-diazeniumdiolates (NONOate), and S-nitrosothiols (RSNO).3, 12-17 A major 
concern for NO donors is the toxicity of byproducts that are generated upon NO proliferation.  
NONOates have been shown to form N-nitrosamines by back-reaction of some fraction of the NO 
released, and most nitrosamines are carcinogenic.26, 27 RSNOs, on the other hand, are NO releasing 
agents that have the least toxicity-related issues. Most concerns arise from the use of synthetically 
derived RSNOs and the concentration that humans can be exposed to, which is also an issue with 
other types of NO donors.21 
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To circumvent any toxicity-related issues, this work utilizes an endogenous RSNO, S-
nitrosoglutathione (GSNO), that is present in human blood at a concentration between 0.02-0.20 
µM, serving as a carrier of NO.20, 28, 29  Upon liberation of NO, the two most common products are 
glutathione (GSH) and glutathione disulfide (GSSG), which are also found in human blood at 
approximately 17 µM and 3 µM, respectively.29 GSNO is a primary RSNO that can decompose 
and liberate NO in the presence of certain reducing agents, including trace metal ions (e.g., 
Cu(I/II)), as well as by thermal degradation and photolysis.28, 30-38  Hence, maintaining stability of 
GSNO as well as other RSNOs over long periods of time can be challenging. 
Herein, the potential long-term stability issues of GSNO are solved by storage within a highly 
viscous and hydrophobic matrix, Vaseline.  Further, initiating and accelerating the release of NO 
from GSNO stored within the Vaseline matrix is studied when mixed with various secondary 
creams containing different NO releasing accelerants/catalysts.  The secondary cream that 
provided the most NO release over a 6 h period contains zinc oxide particles.  Zinc oxide (ZnO) 
particles are widely utilized in pharmaceuticals, cosmetics, textiles, and electronics.39 For example, 
ZnO is used in most topical sunscreens because it can absorb UVB (290-320 nm) and UVA (320-
400 nm) sunlight radiation.40  It is also employed within diaper rash creams as a stringent and 
antimicrobial agent.41, 42 A method was developed to study the NO release characteristics and 
kinetics from the GSNO/Vaseline/ZnO cream formulations over a 6 h period in both dark and light 
settings.  Observed first-order rate constants and half-lives are reported for each formulation and 
scenario studied. 
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2.2 Materials and Methods 
2.2.1 Materials 
L-Glutathione reduced (GSH), hydrochloric acid (HCl), and sodium nitrite were purchased from 
Sigma-Aldrich (St. Louis, MO).  Acetone and xylenes were purchased from Fisher Scientific Inc. 
(Pittsburgh, PA).  Vaseline® Jelly, Unilever, Lot 08226JB00 (Vaseline); Neosporin® + Pain 
Relief Cream, Johnson & Johnson Consumer Inc, Lot 0058LZ  (Neosporin cream); Avalon 
Organics® Intense Defense with Vitamin C Oil-Free Moisturizer, The Hain Celestial Group Inc, 
Lot 618747 (vitamin C cream); and Desitin® Rapid Relief Cream: Zinc Oxide Diaper Rash Cream, 
Johnson & Johnson Consumer Inc, Lot 1577LZ/2 (zinc oxide cream) were purchased from a local 
CVS Pharmacy.  Osmotics Cosmeceuticals Blue Copper 5®, Osmotics LLC, Lot 4248D7 (copper 
cream) were purchased from Amazon.com.  All aqueous solutions were prepared with 18.2 M Ω 
deionized water using a Milli-Q filter (Milli-q purified water) from EMD Millipore (Billerica, 
MA).  Staphylococcus aureus ATCC 25923, Staphylococcus epidermidis ATCC 12228, and 
Pseudomonas aeruginosa ATCC 27853 were obtained from the American Type Culture Collection 
(Manassas, VA). 
 
2.2.2 S-Nitrosoglutathione (GSNO) synthesis 
An adapted method of the procedure reported initially by Hart et al. was used to synthesize 
GSNO.43  Synthesis was completed in the absence of light.  Reduced glutathione (GSH) (4.59 g) 
was dissolved in aqueous HCl (0.5 M, 31.5 mL), cooled to 0°C using an ice bath, and continuously 
purged under nitrogen.  An equal molar amount of sodium nitrite (1.035 g) was added directly to 
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the GSH solution.  After stirring for 40 min at 0°C, ice-cold acetone (10 mL) was added into the 
reaction mixture to precipitate the GSNO.  After stirring for another 10 min, the pink precipitate 
was separated by vacuum filtration.  The resulting pink powder was washed by ice-cold water (3 
× 10 mL) and acetone (3 × 10 mL), respectively.  Finally, the desired GSNO product (3.85 g, 77% 
yield) was obtained after drying under vacuum at room temperature (24°C) for 24 h. GSNO was 
stored at freezer temperature (-20°C) in the dark for any further use. The synthesized GSNO was 
characterized in D2O at room temperature (24°C) by 
1H NMR spectroscopy (Varian 400 MHz 
spectrometer) (Fig 2.1). 1H NMR (400 MHz, D2O): δ 4.63 (app. t, J = 6.2 Hz, 1 H) , 4.02 (dd, J = 
51.2, 12.8 Hz, 2 H), 3.91 (s, 2 H), 3.76 (t, J = 6.4 Hz, 1 H), 2.41 (t, J = 7.6 Hz, 2 H), 2.08 (app. 
nonet, J = 7.6 Hz, 2 H). The purity of prepared GSNO was > 98% based on the characterization of 
the 1H NMR results (Fig. 2.1). 
 
Figure 2.1. 1H NMR Spectrum of synthesized GSNO in D2O.
44 
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2.2.3 Preparation of various wt% GSNO in Vaseline 
The entire preparation of each formulation was completed in the absence of direct light.  A mortar 
and pestle were used to grind GSNO crystals into a fine powder.  The desired mass of fine GSNO 
powder was then weighed out into a mixing vessel.  In the same vessel, the desired mass of 
Vaseline was added.  The fine GSNO powder was then mixed thoroughly with the Vaseline using 
a wooden stirrer for 2.5 min.  The resulting mixture was designated as a primary matrix. 
 
2.2.4 Preparation of various wt% of GSNO in Vaseline for long-term stability studies 
The desired wt% of the primary GSNO/Vaseline matrix was prepared.  The sample was placed 
into a 20 mL amber glass vial with septum cap and wrapped in aluminum foil.  The vial was purged 
with nitrogen gas via the septum top for 5 h.  Samples were then stored in the dark at 24°C for 
extended time periods. 
 
2.2.5 Evaluating stability of GSNO in Vaseline using UV-Vis spectroscopy 
The entire procedure was completed in the absence of direct light.  An aliquot of the 
GSNO/Vaseline primary matrix from the stability study samples was weighed out into a separate 
20 mL amber glass vial.  Five mL of xylenes was added to the vial.  A mixture of xylenes was 
used to dissolve the Vaseline while not dissolving the GSNO.  The vial was shaken on a horizontal 
shaker (Shaker 30, National Labnet Company, Woodbridge, NJ) at 400 RPM for 10 min.  After 
that time, the contents were transferred into a 60 mL separation funnel.  The original sample vial 
was further washed twice with 1.5 - 2.5 mL of Milli-q purified water and the contents were added 
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to the separation funnel.  The total volume of Milli-q purified water used was noted. The contents 
in the separation funnel were gently mixed for 1 min.  Shaking or agitating the solution too much 
caused the Vaseline to crash out of the xylenes/organic layer.  The bottom aqueous layer that 
contained dissolved GSNO was then collected.  The appropriate volume of aqueous sample was 
pipetted into a quartz cuvette such that the absorbance measured would be < 1 at 334 nm.  Beer’s 
Law (A = εbc) and an extinction coefficient of ε334 nm = 922 M-1cm-1  for the GSNO was used to 
calculate the theoretical absorbance for each sample.43  The sample was diluted further if necessary 
to achieve an absorbance of < 1.  UV-Vis spectra were collected using a UV-Vis 
Spectrophotometer (Lambda 35, Perkin-Elmer, MA).  The spectra were obtained by scanning from 
300-500 nm at a scanning speed of 240 nm/min.  Milli-q purified water was used as the blank to 
standardize the baseline absorbance.  The absorbance at 334 nm was used to calculate the 
%recovery of GSNO from the stored GSNO/Vaseline primary matrix.34, 43  
 
2.2.6 Preparation of matrices for NO release measurements 
The entire procedure was completed in the absence of direct light.  The GSNO/Vaseline primary 
matrix was prepared as described above.  In the same mixing vessel, the desired mass of a 
secondary matrix was weighed out such that the ratio of primary to secondary matrix (e.g., 
commercial ZnO cream, Neosporin cream, copper cream, or vitamin C cream) was 27/73.  Both 
matrices were mixed together using a wooden stirrer for 2.5 min.  A small aliquot of the resulting 
matrix was placed inside of a plastic (polystyrene), circular stencil (diameter 5.85 mm, height 0.33 
mm), on top of a glass slide.  The excess matrix was scraped away from the top and the stencil was 
 31 
removed, leaving the matrix at a defined sample size.  A schematic of the matrix sample on the 
glass slide is depicted in Figure 2.2. 
 
Figure 2.2. Schematic of side and top view for a matrix with a defined sample size on a glass slide. 
 
2.2.7 Measuring NO release from matrices 
Nitric oxide release from various mixed matrices was measured using a Sievers 
Chemiluminescence Nitric Oxide Analyzer (NOA) 280i (Boulder, CO).  The NOA was calibrated 
before via a two-point calibration of N2 gas passed through a NOA zero air filter and a standard of 
44.3 ppm NO in N2 gas.  The test matrix mixture was prepared and put onto a small glass slide as 
described above.  The glass slide was then place into an amber NOA sample cell.  The bottom of 
the amber NOA sample cell was filled with Milli-q purified water and the glass slide was placed 
on top of a stage above the water line such that the matrix mixture did not come in contact with 
the water.  The water reservoir was bubbled with N2 gas at a rate of 50 mL/min to humidify the 
NOA sample cell to prevent the matrix from drying out.  The NO generated from the GSNO within 
the Vaseline/cream mixture was swept into the NOA by N2 sweep gas.  For measuring NO release 
of samples at 34°C, the amber NOA sample cell was placed in a 34°C water bath.  All amber NOA 
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sample cells were wrapped in aluminum foil to shield the samples from light exposure.  A 
schematic of measuring NO release is depicted in Figure 2.3. 
 
Figure 2.3. Schematic of the set-up for measuring NO release from matrices.  The reaction cell is 
amber glass, submerged in a 34°C water bath, and wrapped in aluminum foil. 
 
2.3 Results and Discussion 
2.3.1 Preliminary stability study of 10 wt% and 33 wt% GSNO in Vaseline 
Vaseline was chosen as the primary matrix to store and stabilize GSNO.  Vaseline is a 
commercially available matrix consisting of 100% petroleum jelly/petrolatum (white).  Petrolatum 
(white) is insoluble in water because of its extremely hydrophobic nature consisting of saturated 
hydrocarbons.45 Having zero water content is a key factor when considering the storage and 
stability of GSNO.  In the presence of water, GSNO can decompose in several manners.  A 
transnitrosation reaction can occur between GSNO and other thiols to yield GSH and the 
corresponding nitrosated thiol (Fig. 2.4).46, 47 Singh et al. reported that GSNO will decompose in 
the presence of its parent thiol GSH (and there is always a tiny amount of this species present in 
the GSNO preparation) and that the decomposition rate is dependent on the concentration of GSH 
(Fig. 2.4).34 In aqueous solution, GSNO can also react with other reducing agents such as ascorbate 
(ascorbic acid) or catalysts such as iron and copper ions (Fig. 2.4).30-32, 35, 37 
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Figure 2.4. GSNO decomposition reactions that can occur in the presence of water, where (1) is a 
transnitrosation reaction, (2) is a decomposition reaction with GSH, and (3) is a reaction between 
copper ions and GSNO.34, 46-48 
 
Two different concentrations of GSNO in Vaseline, 10 wt% and 33 wt% GSNO, were prepared to 
evaluate the long-term stability of GSNO in the Vaseline matrix at 24°C, in the dark, and in dry 
storage.  UV-Vis spectroscopy was used to determine the stability of GSNO in Vaseline because 
GSNO has a strong absorption peak in the UV region at 334 nm.34, 43  Absorbance (ABS) versus 
wavelength was measured for both 10 wt% and 33 wt% GSNO in Vaseline stability samples on 
day 583 and day 313, respectively (Fig. 2.5a,b).  The % recovery for the 10 wt% GSNO in Vaseline 
on day 583 was 89.8 ± 3.4%.  The % recovery for the 33 wt% GSNO in Vaseline on day 313 was 
87.6 ± 3.5%.  The samples were stored in the dark to avoid any photochemical decomposition of 
GSNO.36 Traditionally, RSNOs are most stable at colder temperatures.  Shishido et al. reported 
increased thermal stability of CysNO in a PEG 400 matrix because a higher viscosity imposes a 
cage effect on the thiyl and NO radical pair such that geminate recombination occurs more often.33, 
49 Hence, the longevity of GSNO stability at 24°C suggests that the dry GSNO being sequestered 
within the viscous Vaseline matrix may increase GSNO’s thermal stability due to favorable 
geminate recombination of the thiyl and NO radical pair. 
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Figure 2.5. Absorbance (ABS) vs. wavelength plots for (a) 10 wt% GSNO and (b) 33 wt% GSNO 
mixed in Vaseline on day 583 and day 313, respectively.  The crossed circle represents the 
theoretical ABS value at 334 nm for 100% recovery of GSNO.  The percent recovery of GSNO 
was calculated to be (a) 89.8 ± 3.4% and (b) 87.6 ± 3.5 based on ABS at 334 nm. Samples were 
stored in a dark, dry environment under N2 gas at 24°C. Data represents the mean ± SD (n = 3). 
 
2.3.2 Initiating NO release using various secondary matrices 
Four different commercially available secondary matrices were chosen for testing because they 
have ingredients that have the potential to assist with NO proliferation from GSNO when mixed 
with the GSNO/Vaseline primary matrix.  The non-prescription matrices selected were 
Neosporin® + Pain Relief Cream (Neosporin cream), Avalon Organics® Intense Defense with 
Vitamin C Oil-Free Moisturizer (vitamin C cream), Osmotics Cosmeceuticals Blue Copper 5® 
(copper cream), and Desitin® Rapid Relief Cream: Zinc Oxide Diaper Rash Cream (zinc oxide 
cream).  The primary matrix (33 wt% GSNO in Vaseline) was mixed with each secondary matrix 
at a 27/73 ratio.  This ratio was chosen primarily based on consistency of the final mixture.  NO 
release for these mixtures at two temperatures was investigated, room temperature (24°C) and a 
temperature closer to the surface of human skin (34°C).50 After mixing the primary and secondary 
matrices, NO release was monitored over a 6 h period using a NOA.  Only the first 6 h of NO 
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release were monitored to simulate a theoretical application period.  Figure 2.6 shows the total 
%NO released from the known amount of GSNO present during the 6 h period for each secondary 
matrix at 24°C and 34°C.  It is clear from the data shown in Figure 2.6 that the zinc oxide cream 
provides a significantly enhanced rate of NO release when mixed with the GSNO/Vaseline mixture 
compared to the other three commercial creams tested. 
 
Figure 2.6. %NO released from 33 wt% GSNO/Vaseline primary matrix mixed with several 
secondary matrices: (a) Neosporin cream; (b) vitamin C cream; (c) copper cream; and (d) zinc 
oxide cream at a 27/73 ratio to yield a final 9 wt% GSNO matrix.  NO release was measured in 
the dark over a 6 h period at both 24°C and 34°C. Data represents the mean ± SD (n = 3). 
 36 
In general, for each final matrix mixture there is a minimum of two known mechanisms by which 
NO is proliferated from GSNO, thermal and via reaction with its parent thiol GSH (a trace amount 
of GSH is always present in the GSNO preparation).34, 51 Only these two reactions take place to 
generate NO in the case where Neosporin is involved.  Based on the ingredients present in the 
Neosporin cream, there are no additional reactions that could likely take place to proliferate NO 
from GSNO.  When Neosporin was mixed with the GSNO/Vaseline mixture, only as small 
percentage of NO was released after 6 h for both temperatures (Fig. 2.6a).  This data shows that 
Neosporin is not capable of releasing an appreciable amount of NO from GSNO because the NO 
generation pathways are limited to the two mentioned above. 
In the case involving the vitamin C cream, there is an additional reaction that could take place to 
increase NO release.  The active ingredient ascorbic acid/ascorbate (serving as a reducing agent) 
is known to enhance NO release from GSNO.30, 32  However, an extremely low %NO release was 
observed (Fig. 2.6b).  The concentration of ascorbic acid in this commercial cream is proprietary 
and unknown.  Therefore, there may not be enough ascorbic acid in the vitamin C cream to release 
an appreciable amount of NO from GSNO because ascorbic acid is a reactant, not a catalyst for 
the NO release reaction.30, 32, 52 Further, the reaction rate between GSNO and ascorbic acid may be 
hindered by other species  present in the Vitamin C cream.  It is known that ascorbic acid can be 
readily oxidized by moisture, light, heat, and metal ions.53, 54 For this reason, cosmetic formulations 
use different chemicals or additives to stabilize ascorbic acid such as tocopheryl acetate, citric 
acid, boric acid, tartic acid, and glycerine.54 
The %NO released by the copper cream was much lower than expected because copper ions are 
well-known to be a very good catalyst for NO proliferation from RSNOs (Fig. 2.6c).31, 35, 55  Similar 
to the vitamin C cream, there may be a component in the commercial copper cream that inhibits 
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the reaction between the copper ions and GSNO.  One ingredient present in the copper cream is 
protocatechuic acid (PCA).  PCA is known to be a metal ion chelator as well as free radical 
scavenger.56, 57 Therefore, the NO produced may be scavenged or the copper ions are likely 
strongly bound to PCA, not enabling them to serve as a catalyst for NO generation from GSNO. 
The zinc oxide cream released significantly more NO from the GSNO/Vaseline mixture than any 
other secondary matrix tested, at both 24°C and 34°C (Fig. 2.6d).  The zinc oxide cream was 
chosen because McCarthy et al. showed that Zn2+ ions have the capability of releasing NO from 
another RSNO (S-nitroso-N-acetylpenicillamine (SNAP)).58 However, with no reports on Zn2+ 
ions significantly enhancing the proliferation of NO from GSNO, further experimentation was 
needed to determine the true source of NO proliferation from GSNO. 
 
2.3.3 NO release characteristics and kinetics from GSNO using zinc oxide cream 
The first step to better understand the exact agent in the ZnO cream that accelerates the NO release 
from GSNO was to investigate the NO release kinetics using three different starting concentrations 
of GSNO.  An aliquot of the appropriate wt% of GSNO in Vaseline was mixed with the zinc oxide 
cream at a 27/73 ratio such that the final wt% of GSNO in the combined matrix was 3, 6, or 9 wt%.  
NO release was measured at 34°C for 6 h revealing that the NO release profile for each 
concentration was fairly similar (Fig. 2.7a).  Cumulative NO release plotted versus time reveals a 
similar NO release trend for all three concentrations of GSNO tested, exhibiting apparent first-
order kinetics (Fig. 2.7b).  Integration of Figure 2.7a showed that 77.9 ± 3.8%, 75.4 ± 3.8%, and 
74.6 ± 2.2% of the total theoretical NO available was released when employing the 3, 6, and 9 
wt% GSNO final mixtures over a 6 h test period, respectively (Table 2.1).  The observed first order 
 38 
rate constant for the overall NO release kinetics was determined by the cumulative moles of NO 
release for 3, 6, and 9 wt% GSNO in the final mixtures versus time, giving kobs = 0.58 ± 0.01 h
-1 
(t1/2 ~ 1.18 h), kobs = 0.63 ± 0.01 h
-1 (t1/2 ~ 1.10 h), and kobs = 0.64 ± 0.01 h
-1 (t1/2 ~ 1.08 h), 
respectively (Fig. 2.8a-c, Table 2.1). 
 
Figure 2.7. (a) Real-time NO release of 3, 6, and 9 wt% GSNO matrices in the dark at 34°C. (b) 
Cumulative NO release vs. time for 3, 6, and 9 wt% GSNO matrices in the dark at 34°C. 
GSNO/Vaseline primary matrices were mixed with commercial Desitin zinc oxide cream at a 
27/73 ratio to achieve 3, 6, and 9 wt% GSNO final matrices. Data represents mean (n = 3). 
 
Table 2.1. Summary of %NO release in 6 h, first order rate constant (kobs), and half-life (t1/2) for 
3, 6, and 9 wt% GSNO final matrices measured in the dark at 34°C.  GSNO/Vaseline primary 
matrices were mixed with commercial Desitin zinc oxide cream at a 27/73 ratio. (n = 3 separate 
preparations). 
Matrix % NO release in 6 h kobs (h
-1) t1/2 (h) 
3 wt% GSNO 77.9 ± 3.8 0.58 ± 0.01 1.18 
6 wt% GSNO 75.4 ± 3.8 0.63 ± 0.01 1.10 
9 wt% GSNO 74.6 ± 2.2 0.64 ± 0.01 1.08 
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Figure 2.8. Fit of the cumulative NO release versus time of (a) 3 wt% (b) 6 wt%, and (c) 9 wt% 
GSNO matrices to a first-order rate equation, giving (a) kobs = 0.58 ± 0.01 h
-1 (t1/2 ~ 1.18 h), (b) 
kobs = 0.63 ± 0.01 h
-1 (t1/2 ~ 1.10 h), (c) kobs = 0.64 ± 0.01 h
-1 (t1/2 ~ 1.08 h). Data represents mean 
(n = 3). 
 
While it is possible that there could be several different reactions taking place to proliferate NO 
from GSNO, overall the total %NO release, half-life, and rate constant values are very similar for 
all three concentrations of GSNO in the final mixtures (Table 2.1).  Indeed, the measured rate 
constants for each concentration of GSNO are very similar, leading to the conclusion that the rate 
constant is independent of GSNO concentration.  However, the actual rate of reaction is time and 
concentration dependent according to the first-order rate law. 
All of the studies described above were completed in the absence of direct light.  However, for 
practical topical application, the creams have a high chance of being exposed to light.  Therefore, 
the NO release kinetics of the highest GSNO concentration in Vaseline/ZnO cream (9 wt% GSNO 
final cream) were measured in the presence of ambient laboratory light.  More specifically, the 
light source was from fluorescent ceiling lights approximately 2 meters away from the samples 
tested.  In general, the same procedure outlined in Section 2.2.7 was followed.  The only changes 
were that the laboratory light was on during the 6 h NO release measurements, the NOA sample 
cell was clear glass not amber, and no aluminum foil was used to cover the cell.  A direct 
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comparison of the real-time NO release in the dark versus in ambient room light shows a negligible 
difference in the rate of NO generation (Fig. 2.9a-b).  The %NO released over the first 6 h in the 
presence of light was 75.1 ± 3.2%, which is very similar to that observed under dark conditions 
(Table 2.1).  The observed first order rate constant in the presence of light was determined in the 
same manner as described previously, giving kobs = 0.63 ± 0.01 h
-1 (t1/2 ~ 1.10 h), which again is 
very similar to the in dark scenario (Fig. 2.9c, Table 2.1).  One plausible reason why these different 
scenarios yield similar results could be because only the surface of the opaque cream is exposed 
to light and not the bulk of the cream.  This data concludes that the NO release kinetics are not 
significantly impacted by the presence of ambient laboratory lighting. 
 
Figure 2.9. Real-time NO release of 9 wt% GSNO matrices in the dark and in ambient room light 
at 34°C over (a) 6 h and (b) 60 min.  (c) Fit of the cumulative NO release versus time of 9 wt% 
GSNO matrices in ambient room light to a first-order rate equation, giving kobs = 0.63 ± 0.01 h
-1 
(t1/2 ~ 1.10 h). GSNO/Vaseline primary matrices were mixed with commercial Desitin zinc oxide 
cream at a 27/73 ratio to achieve 9 wt% GSNO final matrices. Data represents mean (n = 3). 
 
2.4 Conclusion 
The characteristics and capabilities of preparing different NO releasing topical matrices based on 
storing GSNO as the NO donor in Vaseline have been evaluated.  Long-term storage stability was 
observed for 10 wt% and 33 wt% GSNO mixed in commercial Vaseline at 24°C.  The enhanced 
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stability of GSNO in Vaseline was attributed to the extremely dry storage conditions and the high 
viscosity of the matrix leading to geminate recombination of the radical pair.  Out of four 
secondary matrices tested to promote NO release when mixed with the GSNO/Vaseline primary 
matrix, the commercial Desitin zinc oxide-based cream released the highest percentage of NO at 
both 24°C and 34°C over a 6 h period.  The unexpected low rates of NO release from GSNO in 
the presence of commercial ascorbic acid and copper-containing creams under the same 
experimental conditions were attributed to interferences in the NO release reaction from other 
ingredients present in these matrices.  First-order NO release kinetics were reported for 3, 6, and 
9 wt% GSNO final matrices using the zinc oxide cream as the NO release promoter.  Based on the 
first order rate constants, it was determined that the observed rate constant was independent of 
GSNO concentration.  Comparing the first order rate constants from NO released in the dark versus 
light revealed that the NO release kinetics are not significantly impacted by ambient light. 
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Chapter 3 Antimicrobial Effects of NO Releasing Cream Formulations 
 
Certain sections and figures of this chapter are reprinted from Nitric Oxide, Vol. 90, Nitric oxide 
releasing two-part creams containing S-nitrosoglutathione and zinc oxide for potential topical 
antimicrobial applications, Doverspike, J. C.; Zhou, Y.; Wu, J.; Tan, X.; Xi, C.; Meyerhoff, M. E. 
Copyright 2019, with permission from Elsevier. 
 
3.1 Introduction 
In 1941, Selman Waksman was the first to define the term “antibiotic” as any small molecule made 
by microorganisms that antagonizes the growth of other microbes via a specific Mode-Of-Action.1, 
2 The “golden era” of antibiotic discovery and development occurred from the 1930s to 1960s.3, 4 
Unfortunately, the rise of antibiotic resistant strains caused antibiotic development to rapidly 
decrease during the following decades mainly due to the abuse and misuse of antibiotics.3-5 
According to organizations such as the World Health Organization (WHO) and Centers for Disease 
Control (CDC), antimicrobial resistance has evolved into a global crisis.4-7 
Over the last few decades, several methods have been developed to combat multidrug resistant 
organisms (MDR).  In general, antibiotics are hindered by their specificity toward certain 
strains/types of bacteria.  Therefore, methods such as combination antibiotic therapy have been 
developed.  Combination antibiotic therapy is generalized as using two or more antibiotics to 
broaden the antibacterial spectrum, treat polymicrobial infections, and provide potential 
synergistic effects.3, 8 For topical applications, combination antibiotic therapy is commonly used 
due to the multitude of bacteria strains/types associated with dermal infections.9 
Creams/ointments are often the obvious form of treatment/prevention of topical infections. For 
instance, Neosporin is a commercially available antibiotic cream that utilizes combination 
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antibiotic therapy. Neosporin cream/ointments contain the antibiotics neomycin, polymyxin B, 
and/or bacitracin.10, 11 These are considered as the active ingredients targeting specific bacteria 
expanding the range of bacteria to kill.9  Yet, Neosporin and many other creams/ointments still 
lack the desired broad spectrum antimicrobial killing effects.12 Therefore, treatments exhibiting 
non-selective activity are needed. Specifically, an active agent capable of targeting multiple 
bacteria strains is required. 
An agent capable of meeting the above criteria is nitric oxide (NO).13-20 NO is a free radical 
molecule, naturally synthesized in vivo by the enzyme nitric oxide synthase (NOS).16, 21, 22  When 
fighting an infection, the body’s immune system macrophages produce NO as a host defense 
response to serve as an antimicrobial/antiviral agent.21-23 As a free radical molecule, NO is potent 
against a broad spectrum of bacteria including antibiotic-resistant strains as it can trigger multiple 
reactions leading to bacteria cell death.16, 21, 22  Therefore, assessing the antimicrobial activity of 
NO releasing creams/ointments is necessary due to their potential impact on society. 
This chapter assess the antimicrobial efficacy of previously developed NO releasing cream 
formulations (see Chapter 2) against Staphylococcus aureus, Staphylococcus epidermidis, and 
Pseudomonas aeruginosa, which are commonly associated with wound or burn-wound 
infections.24-26 First, an indirect application method was used to evaluate the antimicrobial effects 
of just the NO generated from the GSNO-containing creams.  This method eliminated any potential 
matrix killing effects from the GSNO-containing creams, to focus on the killing effects from only 
the NO generated.  Second, to investigate the antimicrobial effects from both NO and matrix, a 
direct application study involving pig skin as the model system was conducted.  Third, the synergy 
of combining NO- and antibiotic-containing creams against biofilms was evaluated.  Fourth, to 
further characterize the developed NO releasing formulations, a method was developed to estimate 
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the pH of the NO releasing cream formulations.  Further, the kinetics of NO released from creams 
with varying pH were reported.  Lastly, the antimicrobial efficacy of creams with varying pH were 
assessed. 
 
3.2 Materials and Methods 
3.2.1 Materials 
L-Glutathione reduced (GSH), hydrochloric acid (HCl), sodium nitrite, and sodium bicarbonate 
(NaHCO3) were purchased from Sigma-Aldrich (St. Louis, MO).  Acetone was purchased from 
Fisher Scientific Inc. (Pittsburgh, PA).  LB agar and 10 mM phosphate buffered saline (PBS) (pH 
7.2) were purchased from ThermoFisher Scientific (Grand Island, NY).  Medical grade silicone 
sheeting (non-reinforced, gloss, 0.0127 cm thick) was purchased from BioPlexus Corp. (Ventura, 
CA).  Vaseline® Jelly, Unilever, Lot 08226JB00  (Vaseline); Neosporin® + Pain Relief Cream, 
Johnson & Johnson Consumer Inc, Lot 0058LZ; Avalon Organics® Intense Defense with Vitamin 
C Oil-Free Moisturizer, The Hain Celestial Group Inc, Lot 618747; Desitin® Rapid Relief Cream: 
Zinc Oxide Diaper Rash Cream, Johnson & Johnson Consumer Inc, Lot 1577LZ/2; Lubriderm 
Daily Moisture Lotion, Normal to Dry Skin, Fragrance Free, Johnson & Johnson Consumer Inc; 
and Pond’s Dry Skin Cream, Facial Moisturizer, Unilever were products purchased from a local 
CVS Pharmacy.  Osmotics Cosmeceuticals Blue Copper 5®, Osmotics LLC, Lot 4248D7 and 
Loctite (UK U-05FL) were purchased from Amazon.com.  All aqueous solutions were prepared 
with 18.2 M Ω deionized water using a Milli-Q filter (Milli-q purified water) from EMD Millipore 
(Billerica, MA).  Pork with skin was purchased from a local Chinese supermarket.  Staphylococcus 
aureus ATCC 25923, Staphylococcus epidermidis ATCC 12228, and Pseudomonas aeruginosa 
ATCC 27853 were obtained from the American Type Culture Collection (Manassas, VA). 
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3.2.2 S-Nitrosoglutathione (GSNO) synthesis 
The method used to prepare GSNO was the same as that described in Chapter 2. 
 
3.2.3 Preparation of various wt% GSNO in Vaseline 
The entire preparation of each formulation was completed in the absence of direct light.  A mortar 
and pestle were used to grind GSNO crystals into a fine powder.  The desired mass of fine GSNO 
powder was then weighed out into a mixing vessel.  In the same vessel, the desired mass of 
Vaseline was added.  The fine GSNO powder was then mixed thoroughly with the Vaseline using 
a wooden stirrer for 2.5 min.  The resulting mixture was designated as a primary matrix. 
 
3.2.4 Preparation of NO releasing and other matrices 
The entire procedure was completed in the absence of direct light.  All matrices were mixed 
together using a wooden stirrer for 2.5 min.  The GSNO/Vaseline primary matrix was prepared as 
described above. For indirect application and direct application antimicrobial studies (3.2.5 and 
3.2.7, respectively), the desired mass of a secondary matrix was weighed out into the same mixing 
vessel such that the ratio of primary to secondary matrix (e.g., commercial 13% ZnO cream) was 
27/73.  For direct application anti-biofilm studies (3.2.8), the GSNO/Vaseline primary matrix was 
also mixed with a secondary matrix for a final ratio of 27/73, where the secondary matrix consisted 
of a 67.5/32.5 ratio of Neosporin/40% ZnO cream (final 13% ZnO after mixing with Neosporin).  
For the direct application antimicrobial studies of various formulations with varying pH, several 
additional formulations were prepared.  NaHCO3 was added to the GSNO/Vaseline primary matrix 
such that the final matrix contains 33 wt% GSNO, 16.5 wt% NaHCO3, and 50.5 wt% Vaseline.  
For this new primary matrix, the amount of NaHCO3 was two molar equivalents of GSNO present.  
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The GSNO/NaHCO3/Vaseline primary matrix was mixed with the secondary matrix (e.g., 
commercial 13% ZnO cream) at a 27/73 ratio, yielding 9 wt% GSNO + 4.5 wt% NaHCO3 final 
concentrations.  Another formulation consisted of an equimolar amount of GSH compared to the 
amount of GSNO described in the previous formulation.  GSH was mixed with Vaseline to yield 
a 30.7 wt% GSH in Vaseline primary matrix.  This new primary matrix was mixed with the 
secondary matrix (e.g., commercial 13% ZnO cream) at a 27/73 ratio, yielding a final concentration 
of 8.3 wt% GSH.  Another formulation was created where NaHCO3 was added to the 
GSH/Vaseline primary matrix such that the final yields were 30.7 wt% GSH, 16.5 wt% NaHCO3, 
and 52.8 wt% Vaseline.  The GSH/NaHCO3/Vaseline primary matrix was mixed with the 
secondary matrix (e.g., commercial 13% ZnO cream) at a 27/73 ratio, yielding 8.3 wt% GSH + 
4.5 wt% NaHCO3 final concentrations.  An additional formulation was created with a primary 
matrix consisting of 16.5 wt% NaHCO3, and 83.5 wt% Vaseline.  This primary matrix was mixed 
with the secondary matrix (e.g., commercial 13% ZnO cream) at a 27/73 ratio, yielding 4.5 wt% 
NaHCO3. 
 
3.2.5 Indirect application antimicrobial studies 
Overnight grown bacteria cultures were diluted with 1 × PBS buffer (10 mM, pH 7.2) to 1 × 
105 CFU/mL.  Fifty μL of the diluted culture was spread on to a 6 cm diameter LB agar plate and 
allowed to air dry for 10 min.  Squares, 1.5 cm × 1.5 cm, were cut from the inoculated LB agar 
and place in an empty petri dish.  Separately, medical grade silicone sheeting (0.0127 cm thick) 
was cut into 2.5 cm × 2.5 cm squares.  Using a plastic (polystyrene) stencil to define the matrices 
area (2 cm × 2 cm × 0.033 cm), different mixtures (e.g., GSNO at different wt% in Vaseline mixed 
with commercial zinc oxide cream (with 13 wt% ZnO)) were spread onto the square silicone sheets 
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and the excess was scraped away.  The average mass of matrix on each silicone sheet was 84.9 ± 
3.0 mg (n=6).  The square silicone sheets with the given matrix mixture were placed on top of the 
inoculated LB agar squares and the cover was lightly place on the petri dish.  Samples were 
incubated at 34°C, absent from light, for 6 h.  After incubation, the silicone sheets were removed 
from the top of the LB agar squares.  A circle (diameter 0.8 cm) was punched out using a biopsy 
punch (Tru-punch, Fisher Scientific, Hampton, NH) from the center of the LB agar squares. This 
punched out circle was homogenized in 2 mL of 1 × PBS (10 mM, pH 7.2) in a 15-mL tube using 
a homogenizer (OMNI TH, OMNI International, Kennesaw, GA) at full speed, and 10-fold serially 
diluted.  Five μL of the dilutions were spread on fresh LB agar plate for overnight culturing and 
single colonies were numerated.  A schematic of the antimicrobial study set-up is shown in Figure 
3.1. 
 
Figure 3.1. Side view schematic of the indirect application antimicrobial study configuration 
where (1) represents a matrix (NO releasing cream or other), (2) represents a thin silicone 
membrane/sheet, and (3) represents a LB agar square with bacterial growth cut from a petri dish. 
 
3.2.6 Pig skin treatment 
Pork with skin was purchased in a Chinese supermarket.  The skin requirements were as follows: 
hairless, smooth surface, not burned, and not damaged.  The flesh attached to the skin was removed 
using a scalpel.  The pig skin was stored at -20°C.  Before use in antimicrobial studies, the pig skin 
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was brought to room temperature (24°C) and cut into pieces (approximately 4 cm × 3 cm). The pig 
skin surface was sterilized twice using alcohol wipes in a biosafety hood.  The sterile pig skin was 
allowed to dry for 5 min under the biosafety hood ventilation to remove alcohol residue from the 
pig skin surface.  The sterile pig skin pieces were placed in separate Petri dishes. 
 
3.2.7 Direct application antimicrobial studies on pig skin model 
Overnight grown bacteria cultures were diluted with 1 × PBS buffer (10 mM, pH 7.2) to 
1 × 108 CFU/mL. Fifty μL of the diluted culture was spread on to the surface of each sterile pig 
skin piece and allowed to air dry for 10 min.  Using a plastic (polystyrene) circular stencil to define 
the matrices area (diameter 1.5 cm, height 0.033 cm), different mixtures (e.g., GSNO at different 
wt% in Vaseline mixed with commercial zinc oxide cream (with 13% ZnO)) were spread on to the 
pig skin pieces and the excess was scraped away.  The average mass of matrix on each pig skin 
piece was 68.7 ± 2.7 mg (n = 6).  The cover was lightly placed on the Petri dish.  Samples were 
incubated at 34°C, absent from light, for 6 h total.  After incubation the matrices were removed 
from the pig skin surface using a razor blade.  A circle (diameter 0.8 cm) was punched out using a 
biopsy punch (Tru-punch, Fisher Scientific, Hampton, NH) from the center of where the matrix 
was removed from the pig skin piece. This punched out circle was homogenized in 2 mL of 
1 × PBS (10 mM, pH 7.2) in a 15-mL tube using a homogenizer (OMNI TH, OMNI International, 
Kennesaw, GA) at full speed, and 10-fold serially diluted.  Fifty μL of the dilutions were spread 
on fresh LB agar plates for overnight culturing and single colonies were numerated. 
 
 53 
3.2.8 Direct application anti-biofilm studies on pig skin model 
The biofilm on pig skin model was adapted from Wang et al..27  Briefly, after the pig skin was cut, 
separated, and sterilized (as described above), a sterile 1.5 mL Eppendorf tube was cut to a height 
of 1.5 cm and the top side was glued to the pig skin surface using Loctite (UK U-05FL).  1% of 
overnight grown bacterial culture (Staphylococcus aureus, Staphylococcus epidermidis, or 
Pseudomonas aeruginosa) was inoculated into fresh LB broth and 0.5 mL of this suspension was 
transferred to the tube glued on to the pig skin surface.  The samples were incubated at 37°C for 
24 h.  After 24 h, the liquid and tubing were carefully removed from the pig skin surface.  The 
biofilm developed on the pig skin surface was now ready for testing.  Cream application and 
bacteria enumeration were performed using the same procedure described above (2.2.7). 
 
3.2.9 Measuring relative pH of various cream formulations 
Five hundred mg of all cream formulations were created in triplicate and prepared in separate 15 
mL conical sterile polypropylene centrifuge tubes.  Each sample was mix thoroughly with a 
wooden applicator for 2.5 min.  Milli-q purified water (4.5 mL) was added to each vessel and hand 
shaken for 3 min.  Each sample was centrifuged at 14,000 rpm for 3 min.  Four mL of the 
supernatant fluid was put into separate glass dram vials.  The pH of each solution was measured 
using a pH electrode InLab Routine Pro from Mettler Toledo. 
 
3.2.10 Measuring wt% water within the creams 
Creams were weighed out into glass sample vials.  The entire mass of the matrix plus the sample 
vial was measured.  The samples were dried under vacuum for 7 days.  On the 7th day, samples 
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were re-weighed and the masses subtracted from the original masses on day 0. Results  are shown 
in Table 3.3 (see Results and Discussion section). 
 
3.2.11 Preparation of matrices for NO release measurements 
The entire procedure was completed in the absence of direct light.  After the desired matrix was 
created as described in Section 2.2.4, a small aliquot of the resulting matrix was placed inside of a 
plastic (polystyrene), circular stencil (diameter 5.85 mm, height 0.33 mm), on top of a glass slide.  
The excess matrix was scraped away from the top and the stencil was removed, leaving the matrix 
at a defined sample size. 
 
3.2.12 Measuring NO release from matrices 
Nitric oxide release from various mixed matrices was measured using a Sievers 
Chemiluminescence Nitric Oxide Analyzer (NOA) 280i (Boulder, CO).  The NOA was calibrated 
before via a two-point calibration of N2 gas passed through a NOA zero air filter and a standard of 
44.3 ppm NO in N2 gas.  The test matrix mixture was prepared and put onto a small glass slide as 
described above (2.2.11).  The glass slide was then placed into an amber NOA sample cell.  The 
bottom of the amber NOA sample cell was filled with Milli-q purified water, and the glass slide 
was placed on top of a stage above the water line such that the matrix mixture did not come in 
contact with the water.  The water reservoir was bubbled with N2 gas at a rate of 50 mL/min to 
humidify the NOA sample cell to prevent the matrix from drying out.  The amber NOA sample 
cell was placed in a 34°C water bath. The NO generated from the GSNO within the Vaseline/cream 
mixture was swept into the NOA by N2 sweep gas.  All amber NOA sample cells were wrapped in 
aluminum foil to shield the samples from light exposure. 
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3.3 Results and Discussion 
3.3.1 Indirect application antimicrobial studies 
Indirect application antimicrobial studies were conducted to demonstrate the killing effect of only 
NO released from the 3, 6 and 9 wt% GSNO test mixtures with the Desitin cream containing 13% 
ZnO against Staphylococcus aureus, Staphylococcus epidermidis, and Pseudomonas aeruginosa.  
These three bacteria strains were chosen because they have been shown to be common bacteria 
associated with wound or burn-wound infections.25, 26 The initial concentration of bacteria 
(1×105 CFU/mL) was chosen because it is often associated with infection for open wounds and 
hindering wound closure.28  Figure 3.1 shows a schematic of how the antimicrobial studies were 
performed.  A silicone sheet was employed to keep the matrices from coming into direct contact 
with the bacteria on agar plates such that no additional killing effects from the matrix itself (e.g., 
ZnO particles) would be observed.29 Silicone films were chosen because Ren et al. reported that 
silicone rubber polymers have the highest rate of NO diffusion compared to several other 
biomedical grade polymers.30  The antimicrobial studies were completed in the dark at 34°C with 
an incubation/application period of 6 h. 
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Figure 3.2. (a-c) Antimicrobial study results for Control and 0, 3, 6, and 9 wt% GSNO final 
matrices indirectly applied (with silicone sheet between) to (b) S. aureus, (c) S. epidermidis, and 
(d) P. aeruginosa inoculated LB agar plates in the dark at 34°C for 6 h.  Control means nothing 
was applied to the surface of the inoculated LB agar.  GSNO/Vaseline primary matrices were 
mixed with Desitin zinc oxide cream at a 27/73 ratio to achieve 0, 3, 6, and 9 wt% GSNO final 
matrices. Viable cells were determined via plate counting.  Horizontal dashed line represents the 
LOD (7.96×102 CFU/cm2).  No error bar means the LOD was reached for each trial.  Data 
represents the mean ± SD (n = 3). * p < 0.05, ** p < 0.025, *** p < 0.01, 0 wt% GSNO vs. 3, 6, 
and 9 wt% GSNO. 
 
“Control” in Fig. 3.2 means nothing was applied to the surface of the inoculated LB agar.  The 0 
wt% GSNO sample used in this study served as a second control to determine how much bacteria 
were lost when removing the silicone sheeting from the surface of the LB agar plate (Fig. 3.2a-c).  
All log reduction values of bacterial counts are reported in the order S. aureus, S. epidermidis, P. 
aeruginosa.  Comparing the “Control” columns versus the “0 wt% GSNO” columns in Fig. 3.2a-
c, the average log reduction after removing the silicone sheeting was calculated to be 0.36, 0.37, 
and 0.57, respectively.  Therefore, when no NO is present and the bacteria are only in contact with 
the silicone sheet, very little killing effects are observed.  In Figure 3.2a-c, the columns that do not 
display an error bar indicate that all of the bacteria of that strain were killed for each trial (n = 3), 
hence reaching the limit of detection for this study (7.96×102 CFU/cm2).  The average log 
reduction between the 0 wt% GSNO and 3 wt% GSNO matrices were 1.55, 1.41, and 1.44; 
between 0 wt% GSNO and 6 wt% GSNO matrices the log reductions were 2.56, 2.31, and 2.44; 
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and between the 0 wt% GSNO and 9 wt% GSNO matrices the log reductions were 2.68, 2.53, and 
2.44, for each of the bacteria examined, respectively. 
In general, the amount of NO released from the 3, 6, and 9 wt% GSNO samples were able to kill 
each bacterial strain (more NO yields greater log reduction).  However, the amount of NO released 
from the 9 wt% GSNO matrix always killed all of the bacteria, therefore reaching the limit of 
detection for this antimicrobial assay.  The true killing potential of the 9 wt% GSNO matrix is, 
therefore, likely greater than that illustrated in Figure 3.2a-c.  Nonetheless, the current study 
demonstrates that NO produced from the ZnO particle enhanced reaction with GSNO is capable 
of killing both gram-positive (S. aureus and S. epidermidis) and gram-negative (P. aeruginosa) 
bacteria to a significant degree.  This phenomenon is not surprising and has been reported several 
times in prior publications because there are multiple mechanisms by which NO can be toxic to 
bacteria.31-36   
 
3.3.2 Direct application antimicrobial studies on pig skin model 
Direct application antimicrobial studies were performed to determine the killing effect of the 
matrices and NO released from the 3, 6, and 9 wt% GSNO mixtures with the Desitin cream 
containing 13% ZnO against Staphylococcus aureus, Staphylococcus epidermidis, and 
Pseudomonas aeruginosa.  The killing effect of a commonly used antibiotic cream (Neosporin) 
was also determined against each bacteria strain as a comparison.  Neosporin cream contains the 
active antibiotics neomycin and polymyxin B which are mainly effective against gram-negative 
bacteria strains.9 The indirect application antimicrobial studies did not allow the matrices to come 
in to direct contact with the bacteria.  Therefore, any killing effect observed was only from the NO 
and not from the matrices.  For the current study, the matrices were spread directly on the surface 
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of inoculated pig skin.  Thus, any killing effects from the matrices (e.g., ZnO particles, antibiotics) 
would be observed in addition to NO (if present).  The direct application antimicrobial studies 
were completed in the absence of light at 34 °C with an incubation/application period of 6 h.  The 
same matrices studied in the indirect application antimicrobial studies were used for the current 
study in addition to Neosporin.   
 
Figure 3.3. (a-c) Antimicrobial study results for No Cream, Neosporin, and 0, 3, 6, and 9 wt% 
GSNO final matrices directly applied to (a) S. aureus, (b) S. epidermidis, and (c) P. aeruginosa 
inoculated pig skin pieces in the dark at 34°C for 6 h.  No Cream means nothing was applied to 
the surface of the inoculated pig skin.  GSNO/Vaseline primary matrices were mixed with Desitin 
zinc oxide cream at a 27/73 ratio to achieve 0, 3, 6, and 9 wt% GSNO final matrices. Viable cells 
were determined via plate counting.  Data represents the mean ± SD (n = 3). * p < 0.05, ** p < 
0.025, *** p < 0.01, 0 wt% GSNO vs. 3, 6, and 9 wt% GSNO. 
 
“No Cream” in Figure 3.3 means nothing was applied to the surface of the inoculated pig skin.  
The 0 wt% GSNO sample used in this study served as a control to determine how much bacteria 
were killed when in direct contact with just the ZnO-containing cream and no NO or antibiotics 
present (Fig. 3.3a-c).  All log reduction values of bacterial counts are reported in the order S. 
aureus, S. epidermidis, P. aeruginosa.  Comparing the “No Cream” columns versus the “0 wt% 
GSNO” columns in Fig. 3.3a-c, the average log reduction was calculated to be 1.07, 1.58, and 
1.36, respectively.  Therefore, ZnO present in the commercial Desitin cream does induce a >1 log 
unit reduction for all bacteria strains.  These observations are not surprising, the killing effect that 
ZnO has on several different bacteria strains has been previously reported.29, 37  The average log 
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reduction between the 0 wt% GSNO and Neosporin matrices were 0.23, N/A, and 1.02; between 
0 wt% GSNO and 3 wt% GSNO matrices the log reduction values were 1.35, 1.12, and 0.76; 
between 0 wt% GSNO and 6 wt% GSNO matrices they were 2.34, 1.45, and 1.06; and between 
the 0 wt% GSNO and 9 wt% GSNO matrices the log reduction values were were 2.47, 1.83, and 
1.34, for each of the bacteria examined, respectively. 
The data presented in Fig. 3.3 shows that the NO releasing creams can match or exceed the killing 
effect of a commonly used antibiotic cream (Neosporin), especially for S. aureus and S. 
epidermidis (both are gram-positive strains).  As mentioned previously, the active antibiotics 
present in Neosporin are mainly effective against gram-negative bacteria strains such as P. 
aeruginosa.9  This phenomenon is confirmed by the data shown in Fig. 3.3.  Overall, NO releasing 
creams directly applied to inoculated pig skin exhibit greater killing effects on S. aureus, S. 
epidermidis, and P. aeruginosa compared to Neosporin. 
 
3.3.3 Evaluate synergy of combining NO and antibiotics to kill biofilm 
Ren et al. showed that using NO and antibiotics together was able to kill much more bacteria than 
just NO alone.38  This prior report demonstrated significant synergy when combining NO release 
with various antibiotics.  Therefore, the goal for the current study was to evaluate the synergy of 
combining NO- and antibiotic-containing creams.  Direct application anti-biofilm studies were 
performed to determine the synergy of combining NO- and antibiotic-containing creams against 
24 h Staphylococcus aureus, Staphylococcus epidermidis, and Pseudomonas aeruginosa biofilms 
on a pig skin model.  A moisturizer cream was used as a control to evaluate how much biofilm 
was removed/killed during the removal of any cream from the pig skin surface because it contains 
no anti-biofilm agents.  Neosporin containing the active antibiotics neomycin and polymyxin B 
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was evaluated against each biofilm.  The NO releasing cream utilized for the current study was the 
9 wt% GSNO final matrix used in both the indirect and direct application antimicrobial studies 
(Sections 3.3.1 and 3.3.2) and designated as formulation (a) in Fig. 3.4.  The NO- and antibiotic-
containing cream formulation used for this study was described in detail in Section 3.2.4.  This 
formulation contains GSNO, ZnO, and Neosporin in the final matrix and is designated as 
formulation (b) in Fig. 3.4.  Note that both formulation (a) and (b) contain the same wt% of GSNO 
and ZnO. The direct application anti-biofilm studies were completed in the absence of light at 
34 °C with an incubation/application period of 6 h. 
 
Figure 3.4. (a-c) Anti-biofilm study results for No Cream, Moisturizer, Neosporin, formulation 
(a), and formulation (b) matrices directly applied to 24 h (a) S. aureus, (b) S. epidermidis, and (c) 
P. aeruginosa biofilms on pig skin pieces in the dark at 34°C for 6 h.  No Cream means nothing 
was applied to the surface of biofilms.  Formulations (a) = 9 wt% GSNO + ZnO Cream: GSNO-
Vaseline/13% ZnO cream mixed at 27/73 ratio.  Formulation (b) = 9 wt% GSNO + ZnO Cream + 
Neosporin: Neosporin cream/40% ZnO cream, 67.5/32.5; GSNO-Vaseline/Neosporin-ZnO cream 
mixed at 27/73 ratio.  Viable cells were determined via plate counting.  Data represents the mean 
± SD (n = 3). * p < 0.05, ** p < 0.025, *** p < 0.01, 0 wt% GSNO vs. 3, 6, and 9 wt% GSNO. 
 
“NO Cream” in Fig. 3.4 means nothing was applied to the surface of the biofilm on the pig skin 
piece.  The “Moisturizer” sample was used to determine how much biofilm was removed/killed 
during the removal of any cream from the pig skin surface (Fig. 3.4a-c).  All log reduction values 
of bacterial counts are reported in the order S. aureus, S. epidermidis, P. aeruginosa.  Comparing 
the “No Cream” columns versus the “Moisturizer” columns in Fig. 3.4a-c, the average log 
reduction was calculated to be 2.13, 3.28, and 3.14, respectively.  Therefore, a significant amount 
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of bacteria is removed/killed during removal of a cream from the surface of the pigskin/biofilm.  
However, greater log reductions are observed for all other formulations utilized during this study 
(Fig. 3.4).  Comparing the Moisturizer control versus the Neosporin sample demonstrates the 
killing effect of only antibiotics neomycin and polymyxin B have against the biofilms.  The 
average log reduction was calculated to be 0.27, 0.81, and 0.17, respectively.  These relatively low 
log reduction values are to be expected, because biofilms inherently resist antibiotics.39 Comparing 
the Moisturizer control versus formulation (a) demonstrates the killing effect of only NO and ZnO 
against the biofilms.  The average log reduction was calculated to be 1.98, 1.55, and 1.16, 
respectively.  These results show that NO and ZnO have a greater anti-biofilm killing effect 
compared to only the antibiotics neomycin and polymyxin B present in Neosporin.  Comparing 
the Moisturizer control versus formulation (b) demonstrates the killing effect of combining NO, 
ZnO, and antibiotics (neomycin and polymyxin B) have against biofilms.  The average log 
reduction was calculated to be 2.00, 1.89, and 3.34, respectively.  The log reduction values that 
formulation (a) achieved compared to formulation (b) indicates that only the killing effect against 
the P. aeruginosa biofilm was significant.  This phenomenon make sense because P. aeruginosa 
is a gram-negative bacteria and the antibiotics neomycin and polymyxin B are mainly effective 
against gram-negative bacteria.9  Therefore, the significantly greater synergistic killing effect of 
combining NO plus the antibiotics neomycin and polymyxin B against P. aeruginosa was to be 
expected because S. aureus and S. epidermidis are both gram-positive bacteria strains. 
 
3.3.4 Evaluate pH of NO releasing creams 
Traditionally, GSNO is synthesized from its parent thiol glutathione (GSH) under acidic conditions 
to yield a fully protonated product (Section 3.2.2).  The most acidic carboxylic acid on GSH has a 
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predicted pKa of 1.94 according to ChemAxon.  After conversion to GSNO, the predicted pKa 
lowers to 1.60.  The pH of 1 mM solutions of GSNO and GSH are <4 (Table 3.1).  This knowledge 
draws concern to the relative pH of the NO releasing creams containing GSNO when potentially 
used for direct application to the skin. The final 9 wt% GSNO formulation created from 33 wt% 
GSNO in Vaseline mixed with 13% ZnO Desitin cream at a 27/73 ratio, is 20.0 ± 1.5 wt% water 
(Table 3.3).  Based on the solubility of GSNO in water (20 mg/mL), the aqueous phase is super 
saturated with GSNO.  Therefore, the relative pH of the final 9 wt% GSNO matrix is potential 
highly acidic. 
Table 3.1. Average pH of 1 mM GSNO, GSH, and SNAP 
solutions. Data represents the mean ± SD (n = 3). 
Solution (1 mM) pH 
GSNO 3.36 ± 0.01 
GSH 3.61 ± 0.03 
 
This formulation is considered a water-in-oil emulsion (w/o) because the dominate phase is oil-
based.  For w/o emulsions, the pH cannot be accurately determined by submerging a traditional 
pH probe in an aliquot of the w/o emulsion because the dominant phase is not aqueous-based.  As 
consequence, to assess the relative pH of the w/o emulsion NO releasing cream, the most extreme 
condition in which all of the GSNO saturates the aqueous phase of the cream was considered and 
the pH was measured.  Refer to Section 3.2.9 for the specific procedure.  Briefly, each formulation 
was diluted at a 1:10 ratio in purified water, hand shaken for 3 min, centrifuged for 5 min, and then 
the pH of the supernatant (aqueous phase) was measured using a calibrated pH electrode/meter 
(Table 3.2).  The pH of several moisturizers and other commercially available creams/emulsions 
were measured as controls using this method. 
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It was determined that the relative pH of the final 9 wt% GSNO matrix was 2.92 ± 0.02.  This pH 
was considered too acidic and therefore needed to be increased to a more neutral pH for potential 
topical skin applications.  To increase the relative pH, sodium bicarbonate (NaHCO3) was added 
because it is a weak base and is commonly used to control the acid-base balance in cosmetic 
formulations.  To achieve a neutral pH, the amount of NaHCO3 added to the existing formulation 
was 2 molar equivalents of the amount of GSNO (Table 3.2).  More specifically, NaHCO3 was 
added to the 33 wt% GSNO in Vaseline primary matrix to achieve a new primary matrix of 33 
wt% GSNO and 16.5 wt% NaHCO3 in Vaseline.  Then, this new primary matrix was mixed at a 
27/73 ratio with the 13% ZnO Desitin cream to yield the final neutral pH NO releasing cream 
formulation of 9 wt% GSNO + 4.5 wt% NaHCO3. 
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Table 3.2. Average pH of formulations diluted 1:10 in purified water. Data represents the mean ± 
SD (n = 3). 
Formulation pH 
9 wt% GNSO: 27/73 ratio of 33 wt% GSNO in Vaseline/13% ZnO Desitin cream 2.92 ± 0.02 
Avalon Organics® Intense Defense with Vitamin C Oil-Free Moisturizer 4.87 ± 0.02 
Osmotics Cosmeceuticals Blue Copper 5® 4.96 ± 0.02 
Neosporin® Dual Action Cream + Pain Relief 5.30 ± 0.04 
9 wt% GNSO + 4.5 wt% NaHCO3: 27/73 ratio of 33 wt% GSNO and 16.5 wt% 
NaHCO3 in Vaseline/13% ZnO Desitin cream 
6.98 ± 0.01 
Milli-q purified water 6.98 ± 0.04 
Desitin® Rapid Relief Cream: Zinc Oxide Diaper Rash Cream 7.44 ± 0.06 
Lubriderm® Daily Moisture Lotion 7.56 ± 0.06 
Pond’s® Dry Skin Cream 7.70 ± 0.08 
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Table 3.3. Summary of wt% water content for various creams/emulsions and their corresponding 
classifications of water-in-oil (w/o) or oil-in-water (o/w) emulsions.  Data represents the mean ± 
SD (n = 3). 
Matrix wt% water Classification 
9 wt% GNSO: 27/73 ratio of 33 wt% GSNO in Vaseline/13% ZnO 
Desitin cream 
20.0 ± 1.5 w/o 
Avalon Organics® Intense Defense with Vitamin C Oil-Free 
Moisturizer 
71.1 ± 0.3 o/w 
Osmotics Cosmeceuticals Blue Copper 5® 72.9 ± 2.5 o/w 
Neosporin® Dual Action Cream + Pain Relief 73.8 ± 0.1 o/w 
9 wt% GNSO + 4.5 wt% NaHCO3: 27/73 ratio of 33 wt% GSNO 
and 16.5 wt% NaHCO3 in Vaseline/13% ZnO Desitin cream 
20.5 ± 1.9 w/o 
Desitin® Rapid Relief Cream: Zinc Oxide Diaper Rash Cream 27.7 ± 2.2 w/o 
Lubriderm® Daily Moisture Lotion 85.2 ± 0.5 o/w 
Pond’s® Dry Skin Cream 66.3 ± 0.3 o/w 
 
3.3.5 NO release kinetics from neutral pH cream containing GSNO and ZnO 
The NO release kinetics were investigated for the neutral pH NO releasing cream formulation to 
determine if the addition of NaHCO3 had any significant effect.  The NO release kinetics of the 
acidic 9 wt% GSNO containing cream was previously report and will be used here for 
comparison.24  An aliquot of the appropriate wt% of GSNO and NaHCO3 in Vaseline was mixed 
with the 13% Zinc Oxide Desitin cream at a 27/73 ratio.  NO release was measured at 34°C for 6 
h revealing that the NO release profile for the neutral pH NO releasing cream was similar to that 
of the acidic NO releasing cream (Fig. 3.5a,b). 
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Figure 3.5. Real-time NO release of 9 wt% GSNO (acidic pH) and 9 wt% GSNO + 4.5 wt% 
NaHCO3 (neutral pH) matrices in the dark at 34°C over (a) 6 h and (b) 60 min.
24  (c) Fit of the 
cumulative NO release versus time for the 9 wt% GSNO + 4.5 wt% NaHCO3 matrix to a first-
order rate equation, giving kobs = 0.66 ± 0.01 h
-1 (t1/2 ~ 1.05 h). Data represents mean (n = 3). 
 
Table 3.4. Comparison summary of %NO release in 6 h, first order rate constant (kobs), and half-
life (t1/2) for 9 wt% GSNO and 9 wt% GSNO + 4.5 wt% NaHCO3 matrices measured in the dark 
at 34°C.24  Data represents the mean ± SD (n = 3 separate preparations). 
Matrix % NO release in 6 h kobs (h
-1) t1/2 (h) 
9 wt% GSNO 74.6 ± 2.2 0.64 ± 0.01 1.08 
9 wt% GSNO + 4.5 
wt% NaHCO3 
79.5 ± 2.3 0.66 ± 0.01 1.05 
 
Cumulative NO release of the neutral pH cream plotted versus time reveal apparent first-order 
kinetics (Fig. 3.5c).  Integration of the neutral pH NO releasing cream plot in Fig. 3.5a showed 
that 79.5 ± 2.3% of the total theoretical NO available was released over the 6 h test period, which 
is similar to that of the acidic NO releasing cream (Table 3.4).  The observed first order rate 
constant of kobs = 0.66 ± 0.01 h-1 (t1/2 ~ 1.05 h) for the overall NO release kinetics of the neutral 
pH NO releasing cream was determined by the cumulative moles of NO release versus time (Fig. 
3.5c, Table 3.4).  The observed first order rate constants for the acidic and neutral pH NO releasing 
cream are very similar, leading to the conclusion that NO release kinetics are not significantly 
impacted by the addition of NaHCO3. 
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3.3.6 Direct application bacteria studies of neutral pH NO releasing cream on pig skin 
To determine if the antimicrobial effects observed from the previous direct application 
antimicrobial studies were from the relative acidity of the matrices or the NO released, further 
direct application antimicrobial studies with the neutral pH NO releasing matrices were conducted.  
These new direct application antimicrobial studies were performed using the same protocol as the 
first direct application antimicrobial studies (Section 3.3.2).  The bacteria strains tested against 
were Staphylococcus aureus, Staphylococcus epidermidis, and Pseudomonas aeruginosa.   
The trials labeled no cream, Neosporin, 0 and 9 wt% GSNO are the same matrices utilized in the 
first direct application antimicrobial studies (Fig. 3.6).  The new matrices tested were 9 wt% GSNO 
+ 4.5 wt% NaHCO3, 8.3 wt% GSH, 8.3 wt% GSH + 4.5 wt% NaHCO3, and 4.5 wt% NaHCO3 
(Fig. 3.6).  The latter three matrices were tested as controls.  The 8.3 wt% GSH matrix contains 
GSH at an equimolar amount of GSNO in the 9 wt% GSNO-containing matrices.  Therefore, the 
acidity of the GSH-containing matrix should be similar because GSH and GSNO only differ in 
molecular structure by the NO moiety.  The 8.3 wt% GSH + 4.5 wt% NaHCO3 matrix again 
contains GSH at an equimolar amount of GSNO in the 9 wt% GSNO-containing matrices and also 
two molar equivalents of NaHCO3.  This control matrix was neutral in pH and without NO release.  
The 4.5 wt% NaHCO3 matrix contained NaHCO3 at two molar equivalents compared to the 
amount of GSNO in the 9 wt% GSNO-containing matrices.  This control matrix was slightly basic 
in pH and without NO release.  The 9 wt% GSNO + 4.5 wt% NaHCO3 contained NaHCO3 at two 
molar equivalents compared to the amount of GSNO.  This matrix was the neutral pH NO releasing 
cream. 
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Figure 3.6. (a) Legend for bar graphs b-d. (b-d) Antimicrobial study results for various matrices 
(see below for detailed matrix list) directly applied to (b) S. aureus, (c) S. epidermidis, and (d) P. 
aeruginosa inoculated pig skin pieces at 34°C, absent from light, for 6 h. Values above bars 
represent log reduction between that sample bar and No Cream sample bar.  Data represents the 
means ± SD (n = 3). 
Detailed Matrix List: 
 No Cream = no cream applied to pig skin 
 Neosporin = antibiotic cream containing the active antibiotics neomycin and polymyxin B 
 0 wt% GSNO = Vaseline/13% ZnO Desitin cream mixed at a 27/73 ratio 
 9 wt% GSNO = GSNO-Vaseline/13% ZnO Desitin cream mixed at a 27/73 ratio 
 9 wt% GSNO + 4.5 wt% NaHCO3 = GSNO-NaHCO3-Vaseline/13% ZnO Desitin cream 
mixed at a 27/73 ratio (amount of NaHCO3 is two molar equivalents of the amount GSNO) 
 8.3 wt% GSH = GSH-Vaseline/13% ZnO Desitin cream mixed at a 27/73 ratio (amount of 
GSH is equimolar to the amount of GSNO in the 9 wt% GSNO matrices) 
 8.3 wt% GSH + 4.5 wt% NaHCO3 = GSH-NaHCO3-Vaseline/13% ZnO Desitin cream 
mixed at a 27/73 ratio (amount of NaHCO3 is two molar equivalents of the amount GSH) 
 4.5 wt% NaHCO3 = NaHCO3-Vaseline/13% ZnO Desitin cream mixed at a 27/73 ratio 
(amount of NaHCO3 is two molar equivalents of the amount GSNO in the 9 wt% GSNO 
matrices) 
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For S. aureus, the addition of NaHCO3 to the 9 wt% GSNO matrix increased the killing effect.  
Sodium bicarbonate has inherent antimicrobial properties, leading to the increased killing effect 
observed.40 For S. epidermidis, the neutral pH NO releasing cream does not reduce the killing 
effect compared to the acidic NO releasing cream.  The same effect was observed for P. 
aeruginosa.  Overall, the neutral pH NO releasing cream (9 wt% GSNO + 4.5 wt% NaHCO3) met 
or exceeded the killing effect of the acidic NO releasing cream (9 wt% GSNO) for all three bacteria 
strains.  Therefore, this data justifies that the first direct application antimicrobial studies using 
only the acidic NO releasing matrices are valid because the relative acidity has no major killing 
effect. 
 
3.4 Conclusion 
The indirect application antimicrobial studies demonstrated the killing effect of only NO released 
from 3, 6, and 9 wt% GSNO final matrices prepared by mixing Desitin zinc oxide cream with the 
GSNO/Vaseline mixture in the dark at 34°C with an application period of 6 h.  S. aureus, S. 
epidermidis, and P. aeruginosa were all affected by the NO released from each NO releasing 
matrix. In general, the more GSNO present (larger amount of NO released) lead to a greater killing 
effect.  The direct application antimicrobial studies on a pig skin model demonstrated the killing 
effect of the matrices and NO released from the 3, 6, and 9 wt% GSNO final matrices.  The 
performance of the NO releasing matrices were compared to a common commercially available 
antibiotic-containing cream, Neosporin.  At minimum, one NO releasing cream formulation was 
able to exceed the killing effect obtained by Neosporin for S. aureus, S. epidermidis, and P. 
aeruginosa.  Combining NO- and antibiotic-containing creams together showed the most 
synergistic killing effect against P. aeruginosa because the antibiotics utilized are mainly effective 
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at killing gram-negative bacteria strains.  Evaluating the relative pH of the final 9 wt% GSNO 
matrix revealed that the cream was acidic because of the acidic nature of GSNO.  However, a 
neutral pH NO releasing formulation was created by adding an appropriate amount of NaHCO3.  
First-order NO release kinetics were examined for the neutral pH NO releasing cream and 
compared to the acidic NO releasing cream, revealing very similar characteristics and kinetics.  
The addition of NaHCO3 to the acidic 9 wt% GSNO cream did not significantly impact the NO 
release kinetics.  A repeat of the first direct application antimicrobial studies on pig skin with the 
addition of the neutral pH NO releasing cream also revealed that the neutral pH NO releasing 
cream was able to match or exceed the killing effect of the acidic pH NO releasing cream for S. 
aureus, S. epidermidis, and P. aeruginosa.  Thus, the relative acidity has no major killing effect. 
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Chapter 4 Investigation of Enhanced NO Release from GSNO in the Presence of ZnO 
 
Certain sections and figures are reprinted from Nitric Oxide, Vol. 90, Nitric oxide releasing two-
part creams containing S-nitrosoglutathione and zinc oxide for potential topical antimicrobial 
applications, Doverspike, J. C.; Zhou, Y.; Wu, J.; Tan, X.; Xi, C.; Meyerhoff, M. E. Copyright 
2019, with permission from Elsevier. 
 
X-ray photoelectron spectroscopy (XPS) experiments were conducted by Dr. Molly MacInnes 
whose name will appear on any future publication of the research described in this chapter. 
 
4.1 Introduction 
Over the past few decades, several ways have been discovered to enhance the rate of NO release 
from S-nitrosoglutathione (GSNO) and other S-nitrosothiols (RSNOs).  Some of these methods 
include photolysis, thermal cleavage, the use of metal ions, and the use of reducing agents.1-11  In 
Chapter 2, a commercial zinc oxide (ZnO)-containing cream demonstrated the ability to 
significantly enhance NO generation from GSNO.  Therefore, further actions/experiments are 
needed to determine the specie(s) responsible for the enhanced NO generation. 
As mentioned above, prior literature has reported the capabilities of various metal ions to enhance 
or suppress NO release from GSNO.  There is a strong likelihood that trace Zn2+ ions are present 
within the commercial ZnO-containing cream used in the studies reported in Chapter 2.  There are 
conflicting reports in the literature whether or not Zn2+ ions are capable of enhancing NO release 
from GSNO or other RSNOs.12-15  A portion of this chapter addresses this discrepancy. 
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Another component studied in detail within this chapter is zinc oxide.  ZnO nanoparticles are the 
key component present in the commercial ZnO cream.  ZnO has many unique physical and 
chemical properties that make it a useful substance for several applications.  Specifically, ZnO is 
a piezo- and pyroelectric metal oxide with high thermal and mechanical stability.16, 17 Its wide band 
gap (3.37 eV) makes ZnO an ideal semiconductor to be used for different sensor and electronic 
applications.16, 17 ZnO particles are also used in cosmetics, sunscreens, and diaper rash creams 
because of its inherent antimicrobial properties, its ability to absorb UVA and UVB sunlight 
radiation, and its relatively low toxicity towards humans and the environment.18, 19 
This chapter is a more detailed follow-up to Chapter 2, focusing on identifying the component in 
commercial zinc oxide cream responsible for the observed enhanced NO proliferation from GSNO.  
The following topics were studied in detail.  First, NO release from GSNO in the presence of Zn2+ 
ions was monitored for their potential enhancement or suppression of NO release.  Second, each 
other component present in the commercial zinc oxide cream was tested for their individual 
potential to enhance NO release from GSNO.  Third, NO release kinetics of 30, 50, and 200 nm 
size ZnO nanoparticles were evaluated under simplistic reaction conditions (dark, 24°C, 7.4 pH).  
Fourth, experimental conditions were simulated to purposely inhibit/block the surface of ZnO to 
gain insight into the manner in which GNSO and ZnO interact.  Lastly, surface analysis of the ZnO 
nanoparticles after interaction with GSNO were completed via X-ray photoelectron spectroscopy 
(XPS) to assess whether any GSH or other product species remained adhered to the surface of the 
particles. 
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4.2 Materials and Methods 
4.2.1 Materials 
L-Glutathione reduced (GSH), hydrochloric acid (HCl), phosphoric acid (H3PO4), sodium nitrite, 
zinc chloride, copper chloride, glycerol, poly(ethylene glycol) (avg. MW=300) (PEG-300), 
magnesium sulfate, alpha tocopheryl acetate, 1,2-octanediol, 1,2-hexanediol, tropolone, Trizma 
base, and potassium hydroxide were purchased from Sigma-Aldrich (St. Louis, MO).  Acetone 
was purchased from Fisher Scientific Inc. (Pittsburgh, PA).  Zinc oxide nanoparticles with an APS 
of 30, 50 and 200 nm were purchased from EPRUI Biotech Co. Ltd. (ShangHai, China).  All 
aqueous solutions were prepared with 18.2 M Ω deionized water using a Milli-Q filter (Milli-q 
purified water) from EMD Millipore (Billerica, MA). 
 
4.2.2 S-Nitrosoglutathione (GSNO) synthesis 
The method used to prepare GSNO was the same as that described in Chapter 2. 
 
4.2.3 Measuring NO release from GSNO in the presence of Zn2+ ions 
All solutions were made with 10 mM Tris-HCl buffer, pH 7.4.  NO release was measured using a 
Sievers Chemiluminescence Nitric Oxide Analyzer (NOA) 280i (Boulder, CO).  The NOA was 
calibrated before via a two-point calibration of N2 gas passed through a NOA zero air filter and a 
standard of 44.3 ppm NO in N2 gas.  The reaction mixtures were analyzed for NO release in the 
absence of light at 24°C.  Two mL of a 1 mM GSNO solution in buffer was added to an amber 
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NOA sample cell (bulk).  After a 1 min equilibration period, 100 μL of 1 mM ZnCl2 was added to 
the bulk.  For the control, 100 μL of the buffer (10 mM Tris-HCl, pH 7.4) was added into the test 
solution.  After 9.5 min, 100 μL of 1 mM CuCl2 was added to the bulk as a positive control.  Each 
solution was bubbled with N2 gas at a rate of 50 mL/min.  NO generated was carried into the NOA 
by a N2 sweep gas. 
 
4.2.4 Measuring NO release from GSNO for component studies 
All solutions were made with 10 mM Tris-HCl buffer, pH 7.4.  NO release was quantitated using 
a NOA in the absence of light at 34°C.  The components studied were the same or similar to those 
known to be present in the commercial zinc oxide cream (Desitin® Rapid Relief Cream: Zinc 
Oxide Diaper Rash Cream).  These included 30 nm ZnO nanoparticles, glycerol, magnesium 
sulfate, tocopheryl acetate, PEG-300, 1,2-octanediol, 1,2-hexanediol, tropolone, and potassium 
hydroxide.  The experimental scheme employed was as follows: 2 mL of a solution containing one 
component was first placed inside of an amber NOA sample cell (bulk solution) at 34°C.  Then, 
100 μL of a GSNO solution was added to the same sample cell.  The bulk solutions contained 10 
μmol of the given test component and the GSNO solution contained 1 μmol of GSNO.  The final 
mole ratio of test component to GSNO was 10:1 µmol.  For each of the aqueous-soluble 
components, 5 mM bulk solutions were made in advance in buffer (e.g., glycerol, magnesium 
sulfate, PEG-300, 1,2-octanediol, 1,2-hexanediol, tropolone, and potassium hydroxide).  The 30 
nm ZnO nanoparticles and tocopheryl acetate are not soluble in aqueous buffer and therefore 
prepared in a different manner to make the bulk solutions. For the ZnO nanoparticles, 0.82 mg 
were added to 2 mL of the buffer (0.41 mg ZnO/mL buffer) inside the amber NOA sample cell 
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and sonicated for 20 s.  For testing tocopheryl acetate, 4.92 μL was added to 2 mL of the buffer 
(2.36 mg tocopheryl acetate/mL buffer) inside the NOA sample cell and sonicated for 20 s.  The 
amber NOA sample cell containing the bulk solution(s) was submerged in a 34°C water bath and 
allowed to equilibrate for 1 min.  After 1 min, 100 μL of a 10 mM GSNO solution was added into 
this bulk solution.  As previously described, the solutions inside the sample cells were bubbled 
with N2 gas at a rate of 50 mL/min and the NO generated was carried into the NOA by a N2 sweep 
gas. 
 
4.2.5 NO release kinetics from GSNO using 30, 50, and 200 nm ZnO nanoparticles 
All solutions were made with 100 mM Tris-HCl buffer, pH 7.4.  NO release was quantitated using 
the NOA in the absence of light at 24°C for 10 h.  ZnO nanoparticles (4.1 mg) with diameters of 
30, 50, or 200 nm were added to 2 mL of buffer inside an amber NOA sample cell (bulk solution).  
After achieving a stable baseline, 100 μL of 50 mM GSNO in buffer was added to the reaction cell 
(2.38 mM final concentration of GSNO after addition to bulk solution).  Each solution was bubbled 
with N2 gas at a rate of 50 mL/min and the NO generated was carried into the NO by a N2 sweep 
gas. 
4.2.6 NO release from GSNO in the presence 30 nm ZnO in Tris–HCL or –H3PO4 buffer 
Nitric oxide release was quantitated using a NOA in the absence of light at 24°C for 25 min.  Thirty 
nm size ZnO nanoparticles (4.1.mg) were added to 2 mL of either 100 mM Tris-HCL or 100 mM 
Tris-H3PO4 buffer, pH 7.4, inside an amber NOA sample cell (bulk solution).  Upon attaining a 
stable baseline, 100 μL of 50 mM GSNO in either 100 mM Tris-HCL or 100 mM Tris-H3PO4 
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buffer, pH 7.4, was added to the respective reaction cells (2.38 mM GSNO final concentration).  
Each solution was bubbled with N2 gas at a rate of 50 mL/min and the NO generated was carried 
into the NOA by a N2 sweep gas. 
 
4.2.7 ZnO nanoparticle preparation for surface analysis via XPS 
All solutions were prepared using 100 mM Tris-HCl buffer, pH 7.4.  The entire procedure and 
reaction was completed in the dark at room temperature (24°C).   ZnO nanoparticles (16.4 mg of 
30 nm particles) were added to 8 mL of buffer inside a 15 mL glass test tube.  Then, 400 μL of 50 
mM GSNO was added to the test tube that was then capped with a rubber septa.  The solution was 
stirred using a stir bar and continuously bubbled with N2 gas at a rate of 50 mL/min via a glass 
pipet.  For a control sample, the same steps were followed as described above, except 400 μL of 
buffer was added to the test tube and not 400 μL of 50 mM GSNO.  The control sample was not 
exposed to GSNO at any point.  Both control and GSNO-containing samples were stopped after 5 
h.  Contents from each test tube were transferred to 15 mL polypropylene conical centrifuge tubes 
separately.  Each glass test tube was washed 3 times with 1 mL of purified water and the contents 
were added to their respective centrifuge tube.  Each tube was centrifuged at 4000 rpm for 1 min.  
The supernatant was decanted off from each tube.  Five mL of purified water was added to each 
centrifuge tube, hand shaken for 10 s, and then centrifuged again.  This washing process was 
completed three times total for both samples.  After washing was completed, both samples were 
dried under vacuum at 24°C for 24 h.  After drying was completed, both samples were ready for 
XPS analysis. 
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4.2.8 X-ray photoelectron spectroscopy (XPS) 
Using a monochromatic Al K alpha source, X-ray photoelectron spectra were collected with a 
Kratos AXIS system with base pressure below 10-9 torr.  To obtain survey and high-resolution 
spectra, pass energies of 160 and 20 eV were used, respectively. All collected data were referenced 
to the binding energy of adventitious carbon (284.6 eV).20 
 
4.3 Results and Discussion 
4.3.1 Investigation of NO release from GSNO in the presence of Zn2+ ions 
An aqueous phase study was undertaken to determine if Zn2+ ions can increase NO proliferation 
from GSNO in the dark at 24°C.  McCarthy et al. reported the NO generation potential of several 
different metal ions from SNAP under physiological pH conditions.12 They discovered that three 
transition metal ions including Co2+, Ni2+, and Zn2+ increased NO release rates, while Fe3+, Mg2+, 
Mn2+, and Pt2+ displayed significantly less NO release enhancement.12 In contrast, Krȩżel et al. 
reported that the stability of GSNO in HEPES buffer (pH 7.4) actually increases in the presence 
of Zn2+ due to the formation of simple coordination complexes.13  Askew et al. observed no 
catalysis capability of Zn2+ on SNAP to proliferate NO, although no data was shown to assess 
whether a non-catalytic reaction can occur.14  More recently, Lutzke et al. reported the NO 
releasing capabilities of over twenty different metal ion species when mixed with GSNO, and Zn2+ 
ions was shown to exhibit no activity.15  In light of these conflicting reports, further investigation 
was needed to better understand the substantial increase in the rate of NO release when the ZnO 
cream is mixed with the GSNO/Vaseline mixture reported in Chapter 2. 
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Figure 4.1. Real-time NO release from 2 mL of 1 mM GSNO after addition of either 100 μL of 1 
mM ZnCl2 or 100 μL of the buffer.  Completed in the dark at 24°C.  All solutions made with the 
buffer 10 mM Tris-HCl (pH 7.4). At t=10.5 min, 100 uL of 1 mM CuCl2 was added as a positive 
control (The ZnCl2 black plot is hidden behind the red plot at t=10.5 min). Data represents the 
mean ± SD (n = 3). 
 
For the current study, ZnCl2 was chosen as the source of Zn
2+ ions.  Figure 4.1 shows NO release 
from GSNO in solution as a function of time with and without Zn2+ ions present in solution.  At 
t=1 min, 100 μL of 1 mM ZnCl2 was added to the bulk solution containing 2 mL of 1 mM GSNO 
resulting in a very small, insignificant burst of NO.  The same insignificant burst was observed 
when the buffer (10 mM Tris-HCl, pH 7.4) was added to the bulk solution.  As a positive control, 
100 μL of 1 mM CuCl2 was added to each scenario at t=10.5 min and a very large burst in NO 
release was observed. A comparison of these two scenarios reveals that Zn2+ ions do not 
appreciably increase NO proliferation from GSNO.  This data supports the findings of Krȩżel et 
al. and Lutzke et al.13, 15 
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4.3.2 Component study of Desitin® Rapid Relief Cream: Zinc Oxide Diaper Rash Cream 
An aqueous phase study was undertaken to determine which agent or agents within the Desitin 
cream were responsible for the accelerated NO release from GSNO discovered in Chapter 2.  A 
simplified system was employed to monitor and measure NO release when GSNO is mixed with 
various components/ingredients present in the commercial zinc oxide cream.  Some ingredients 
present in the Desitin cream were omitted due to their low water solubility (mineral oil, petrolatum, 
beeswax, microcrystalline wax).  The experiments were performed in the presence of 10 mM Tris-
HCl buffer, pH 7.4, at 34°C.  Nine components were studied at a 10:1 μmol ratio with GSNO in 
aqueous solution.  Figure 4.2 shows NO release versus time when 100 μL of 10 mM GSNO was 
added into different bulk solutions containing a given component.  Only the first 10 min of each 
reaction was monitored to determine which component is responsible for the enhanced NO release 
from GSNO.  As shown clearly in Figure 4.2, which compares the NO release profiles of each of 
the components, only the 30 nm ZnO nanoparticles yield a significantly enhanced and prolonged 
NO release from GSNO.  The NO release profiles of the other eight components demonstrate a 
similar profile to the buffer control, where no added components are present.  Moreover, this study 
demonstrates that the other eight components present in the Desitin cream are not significantly 
involved in the enhanced NO release from GSNO. 
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Figure 4.2. Real-time NO release after addition of 100 μL of 10 mM GSNO into 2 mL bulk 
solutions containing a given component.  Experiments were completed in the dark at 34°C.  All 
solutions were made with a 10 mM Tris-HCl buffer (pH 7.4).  The final ratio of component to 
GSNO was 10:1 µmol.  Data represents the mean ± SD (n = 3). 
 
Promoting NO release from GSNO using ZnO nanoparticles has not been reported previously.  
However, very recently Singha et al. demonstrated enhanced and prolonged NO release from 
SNAP-doped CarboSil films with an additional top coating consisting of CarboSil and ZnO 
nanoparticles.21  This demonstrates that ZnO nanoparticles could be capable of promoting NO 
release from other RSNOs.  The data shown here (Fig. 4.2) clearly demonstrates that ZnO 
nanoparticles enhance the NO release from GSNO. 
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4.3.3 NO release kinetics from GSNO using 30, 50, and 200 nm ZnO nanoparticles 
To study the NO release kinetics from GSNO in the presence of different sized ZnO nanoparticles, 
a simplistic reaction model was developed to limit external GSNO decomposition.  Traditionally, 
S-nitrosothiols decompose in the presence of light, at higher temperatures, and in acidic or basic 
solutions.1, 5, 9-11 Thus, the reaction kinetics between GSNO and ZnO nanoparticles were studied 
in the dark, at room temperature (~24°C), and in 100 mM Tris-HCl buffer solution, pH 7.4.  
Plotting cumulative NO release versus time (10 h) when adding 100 μL of 50 mM GSNO to 2.0 
mL of buffer containing 4.1 mg of 30, 50, or 200 nm size ZnO nanoparticles reveals zero order 
reaction kinetics, meaning that the reaction rate is equal to the rate constant (kobs) (Fig. 4.3).  The 
relative ZnO surface area available during each reaction is not directly proportional to the reaction 
rate (Table 4.1).  The presence of the 30 nm size ZnO nanoparticles increases the reaction rate by 
a factor of 2.78 compared to having no ZnO present.  Overall, the reaction rate does increase as 
ZnO nanoparticle size decreases.  
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Figure 4.3. Cumulative NO release vs. time for no ZnO, 30, 50, and 200 nm size ZnO 
nanoparticles in the dark, at 24°C, in 100 mM Tris-HCL, pH 7.4 (buffer).  At t=0 min, 100 μL of 
50 mM GSNO was introduced to 2.0 mL of buffer containing 4.1 mg of 30, 50, or 200 nm size 
ZnO nanoparticles. No ZnO means no ZnO was present and NO release was caused by natural 
GSNO decomposition in the dark, at 24°C, in 100 mM Tris-HCL buffer, pH 7.4.  The first hour of 
NO release was removed due to inconsistent initial NO release rates.  Error bars were omitted for 
clarity.  Data represents mean (n = 3). 
 
Table 4.1. Summary of rate constant (kobs) measured and the available surface area of ZnO present 
for trials containing no ZnO, 30, 50, and 200 nm size ZnO nanoparticles; where at t=0 min, 100 
μL of 50 mM GSNO was introduced to 2.0 mL of 100 mM Tris-HCL buffer, pH 7.4, containing 
4.1 mg of 30, 50, or 200 nm size ZnO nanoparticles.  Trials were completed in the dark at 24°C.  
No ZnO means no ZnO was present.  Data represents the mean ± SD (n = 3). 
ZnO size (nm) kobs (nmol h-1) Surface area of ZnO (cm2) 
no ZnO 5.07 ± 0.09 N/A 
30 15.86 ± 0.18 1461.68 
50 14.65 ± 0.04 877.01 
200 6.10 ± 0.10 219.25 
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4.3.4 Comparing NO release from GSNO using ZnO under Tris–HCl and –H3PO4 
A study was completed to determine if GSNO needs to have unblocked access to the surface of 
ZnO in order to promote NO release.  Literature has shown that phosphoric acid (H3PO4) or like 
groups (HPO4
2-) readily adsorb and interact with the surface of ZnO at neutral pH.17, 22 Hence, 
utilizing a Tris-based buffer where the acid component can be interchanged between –HCl and –
H3PO4, will reveal if GSNO needs unblocked access to the ZnO surface to enhance NO release.  
Figure 4.4 shows the real-time NO release when 100 μL of GSNO is added to a 100 mM Tris-HCl 
or –H3PO4 buffer solution (pH 7.4) containing 30 nM ZnO nanoparticles or when no ZnO is 
present.  When using 100 mM Tris-HCl buffer (pH 7.4), there is a clear difference in the NO 
release profiles when ZnO is present versus when ZnO is not present (Fig. 4.4a).  However, when 
using 100 mM Tris-H3PO4 the NO release profiles are very similar for both scenarios (Fig. 4.4b).  
By changing one chemical of the buffer solution from HCl to H3PO4, the NO release profile 
changes drastically.  Since H3PO4/HPO4
2- favorably interact/adsorb to the ZnO surface at pH 7.4, 
the promoted NO release reaction between GSNO and ZnO does not occur.  This data suggests 
that GSNO needs uninhibited access to the surface of ZnO to promote NO release. 
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Figure 4.4. Real-time NO release after addition of 100 μL of 50 mM GSNO (t=1 min) into 2 mL 
of (a) 100 mM Tris-HCL or (b) 100 mM Tris-H3PO4 buffer (pH 7.4) containing no ZnO or 4.1 mg 
of 30 nm size ZnO nanoparticles.  Completed in the dark at 24°C.  Data represents the mean ± SD 
(n = 3). 
 
4.3.5 Surface analysis of ZnO nanoparticles via X-ray photoelectron spectroscopy 
To characterize the surface of ZnO after NO release from GSNO, X-ray photoelectron 
spectroscopy (XPS) was employed.  There are literature reports of gold and platinum nanoparticles 
catalyzing NO generation from RSNOs.23-25  Jia et al. reported the enhanced rate of NO release 
from GSNO via reaction of gold nanoparticles in a dose-dependent manner.23 Later, Taladriz-
Blanco et al. showed that due to the affinity between gold and thiols, the RS-NO bond breaks when 
in the presence of gold nanoparticles, and subsequently the gold surface is functionalized with the 
corresponding thiol species (as a sub-monolayer).24  More recently, Cao et al. reported enhanced 
NO generation from SNAP and GSNO using 3 nm platinum nanoparticles, and suggested evidence 
of Pt-S bond formation during the reaction.25  Therefore, surface analysis of ZnO after reaction 
with GSNO to promote NO release is necessary to reveal potential evidence of glutathione (thiol) 
attachment to the ZnO surface or Zn-S bond formation. 
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ZnO nanoparticles exposed and not exposed to GSNO were analyzed by XPS.  The specific 
procedure of how each were prepared can be found in Section 4.2.7, above.  Briefly, 400 μL of 50 
mM GSNO was added to 16.4 mg of 30 nm ZnO nanoparticles in 8 mL of 100 mM Tris-HCl 
buffer, pH 7.4, in the dark at 24°C.  The reaction was stopped after 5 h and the ZnO nanoparticles 
were thoroughly washed and dried under vacuum for XPS analysis.  Control ZnO nanoparticles 
were prepared in the same manner except, 400 μL of buffer was added and not 400 μL of 50 mM 
GSNO.  The control ZnO nanoparticles were not exposed to GSNO. 
 
Figure 4.5. High-resolution (a) S 2p, (b) Zn 2p, (c) O1s, and (d) N 1s XP spectra of 30 nm size 
ZnO nanoparticles exposed and not exposed to GSNO in 100 mM Tris-HCl buffer (pH 7.4) in the 
dark at 24°C for 5 h. 
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The S 2p spectra for both ZnO nanoparticles exposed and not exposed to GSNO detect no signal 
(Fig 4.5a).  No detection means that glutathione (thiol) is not adsorbed or bonded to the surface of 
ZnO.  If there was evidence of Zn-S bond, there would be an S 2p3/2 and S 2p1/2 doublet between 
162-167 eV.26-29  The Zn 2p3/2 and Zn 2p1/2 signals at ~1021 and 1044 eV are consistent with ZnO 
(Fig. 4.5b).27 The O 1s spectra are consistent with a signal at ~530 eV from lattice oxygen (O2-) in 
ZnO and the signal at ~532.7 is from hydroxyl groups or chemisorbed oxygen (Fig. 4.5c).27  There 
is a difference in the N 1s spectra between the ZnO exposed and not exposed to GSNO (Fig 4.5d).  
For the ZnO exposed to GSNO, the N 1s signal spans from 397-401 eV and corresponds to the 
combination of two peaks assigned to N-H and N-C bonds (Fig. 4.5d).30  Since there is no S 2p 
signal from the ZnO that was exposed to GSNO, the N 1s signal must originate from the primary 
amine in the Tris buffer.  Therefore, because there is no N 1s signal from the ZnO not exposed to 
GSNO and only exposed to the buffer, means that when ZnO and GSNO react to promote NO 
release, it allows the buffer to more favorably adsorb to the surface of ZnO.  The lack of any S 2p 
signal from the ZnO exposed to GSNO suggests no thiol attachment post-NO proliferation as seen 
previously when using gold or platinum nanoparticles. 
 
4.4 Conclusion 
It was determined that Zn2+ ions have little or no effect on NO proliferation from GSNO in pH 7.4 
buffer at 24°C.  Further, a thorough component study of the Desitin zinc oxide cream suggests that 
the ZnO nanoparticles present are primarily responsible for increased NO proliferation from 
GSNO.  A study of the NO release kinetics from GSNO in the presence of 30, 50, and 200 nm size 
ZnO nanoparticles in the dark, at 24°C, and in neutral pH conditions revealed zero order kinetics 
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during the first 10 h of reaction.  Also, the available ZnO surface area is not directly proportional 
to the reaction rate, but the reaction rate does increase as ZnO nanoparticle size decreases.  A study 
comparing the NO release profiles of using Tris-HCl buffer versus Tris-H3PO4 buffer revealed that 
GSNO needs uninhibited access to the surface of ZnO to promote NO release because 
H3PO4/HPO4
2- adsorb to the ZnO surface and cause NO release to significantly decrease.  Lastly, 
surface analysis of ZnO using XPS after exposure to GSNO showed no evidence of thiol 
attachment or Zn-S bond formation. 
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Chapter 5 Hub Region Disinfecting NO Releasing Insert for Tunnel Dialysis Catheters 
 
The content of this chapter includes experiments conducted by Shale Mack, Amy Lou, and Blake 
Stringer.  These individuals were undergraduate researchers in the Meyerhoff laboratory working 
under the direction of this Ph.D. candidate, and their names will appear on any future publication 
of the research described in this chapter. 
 
5.1 Introduction 
Tunneled dialysis catheters (TDCs) are commonly utilized for patients with End Stage Renal 
Disease (ESRD) that require hemodialysis (HD) treatments.  Even though it is generally accepted 
that TDCs are the least desirable form of dialysis vascular access, in 2010 approximately 80% of 
patients started HD treatment using a TDC and it has remained relatively unchanged since then.1  
One of the major complications associated with TDCs is blood stream infections (BSIs).  BSIs 
caused by TDCs has continued to be an important clinical issue that leaves patients with substantial 
morbidity, mortality, expense, and a decrease in their quality of life.2 
For long-term TDCs, BSIs predominately occur from bacteria/biofilm growth via the intraluminal 
route because of hub contamination.3  The most favored treatment of foreign body-related infection 
is removal of the foreign body (TDC), however this may not be practical for the patient.  Thus, 
methods and devices have been developed that treat/prevent BSIs related to TDCs.  A few notable 
treatment/prevention methods include antimicrobial lock therapy, Tego Needlefree Hemodialysis 
Connector plus Curos Disinfecting Cap for Tego, and a ClearGuard HD Antimicrobial Barrier 
Cap. 
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Antimicrobial lock therapy (ALT) involves infusing a highly concentrated antibiotic solution into 
the catheter lumen for a minimum of 2-4 h.2, 4 Although there is no Food and Drug Administration 
(FDA) approved ALT, ALT practice has exhibited significant benefit to those with TDC.2  
Difficulty arises for ALT when microbial biofilm is already present in the catheter lumen due to 
the inability of antibiotics to penetrate and kill a biofilm.  Certain chemicals like citrate and 
ethylenediaminetetraacetic acid (EDTA) have been added to help disrupt the biofilm, but high 
rates of ALT failure still occur with Staphylococcus aureus, Pseudomonas aeruginosa, and 
Candida bacteria.2, 5, 6 
A recent study compared the performance of two FDA approved devices in relation to the rate of 
BSIs.  These devices included the combination of Tego Needlefree Hemodialysis Connector 
(Tego) plus Curos Disinfecting Cap for Tego (Curos) and ClearGuard HD Antimicrobial Barrier 
Cap (ClearGuard).7  Tego is a device that attaches to the hub and aims to prevent infection by 
using a “closed” system by reducing catheter hub manipulation.7, 8  Curos is a port protector that 
utilizes 70% isopropanol to kill bacteria on the surface of Tego.7, 9 ClearGuard is a device with a 
protruding rod and threads that are coated with chlorhexidine.7, 10  Chlorohexidine is a well-known, 
broad spectrum antimicrobial agent with minimal risk of developing resistant bacteria strains.7, 10  
After a 13 month long study, the ClearGuard had a significantly lower BSI rate of 0.28 positive 
blood cultures (PBC) per 1000 TDC-days versus 0.75 PBC per 1000 TDC-days for Tego + Curos.7  
The potential downfall of the Tego + Curos device is that only the outer surface of the catheter 
hub is targeted.  A potential downfall of the ClearGuard product is that chlorhexidine has trouble 
dispersing and killing biofilms.11 
A device that retains the positive characteristics (effective broad spectrum antimicrobial agent, 
minimal risk of developing resistant bacteria strains) to prevent BSIs but also solves prior device 
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short-comings (effectiveness against biofilms) is one that involves the use of nitric oxide. Nitric 
oxide (NO) is an endogenously produced, free radical gas molecule that is synthesized by the 
enzyme nitric oxide synthase (NOS).12-15  The body naturally produces NO when fighting an 
infection via immune system macrophages.13, 14  NO is highly effective against a broad spectrum 
of bacteria including antibiotic-resistant strains because there are several mechanisms/reactions 
that can lead to cell death.12, 13, 16 
Nitric oxide is also effective at dispersing/displacing biofilms.17-20  One example involves NO 
released from intravascular catheters fabricated with S-nitroso-N-acetyl-D-penicillamine (SNAP) 
doped CarboSil polymer against S. aureus biofilms.20  The amount of bacteria were evaluated after 
catheter segments were subjected to 7 d in a drip-flow bioreactor.  A 5 log unit reduction was 
achieved compared to control catheters with no NO release.20  Therefore, a NO releasing insert 
device that could disinfect the inner lumen of TDCs has great potential for preventing BSIs because 
of its inherent antimicrobial non-specificity, as well as biofilm dispersal and killing capabilities. 
Herein, the NO releasing characteristics of various NO releasing insert devices are evaluated as 
well as their antimicrobial efficacy against S. aureus in a simulated catheter hub model.  The most 
promising NO releasing insert was also evaluated for stability of the NO-donor molecule after 
subjection to different sterilization methods.  The antimicrobial efficacy of the most promising NO 
releasing insert formulation was tested in real hemodialysis catheter hubs against both gram-
negative (P. aeruginosa) and gram-positive (S. aureus) bacteria strains.  Further, two 14-d long 
sheep studies compared the antimicrobial/anti-biofilm capabilities of the chosen NO releasing 
insert versus a control of a normal hemodialysis catheter cap and versus a commercially available 
antimicrobial cap that utilizes the antimicrobial agent chlorhexidine. 
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5.2 Materials and Methods 
5.2.1 Materials 
L-Glutathione reduced (GSH), hydrochloric acid (HCl), sodium nitrite, and polyethylene glycol 
(MW = 3,350) were purchased from Sigma-Aldrich (St. Louis, MO).  Acetone; DOWSIL 3140, 
MIL-A-46146 RTV Silicone Coating; Dow Corning Silastic Laboratory Tubing (ID 0.058" × OD 
0.077", 2415542); and Helix Medical Inc. Silicone Tubing (0.125" × 0.250", 6001121) were 
purchased from Fisher Scientific Inc. (Pittsburgh, PA).  Male Luer Lock Injection Site caps 
(80149) were purchased from Qosina (Ronkonkoma, NY).  LB agar and 10 mM phosphate 
buffered saline (PBS) (pH 7.2) were purchased from ThermoFisher Scientific (Grand Island, NY).  
Zinc oxide nanoparticles (APS 30 nm in diameter) were purchased from EPRUI Biotech Co. Ltd. 
(ShangHai, China).  All aqueous solutions were prepared with 18.2 M Ω deionized water using a 
Milli-Q filter (Milli-q purified water) from EMD Millipore (Billerica, MA).  Staphylococcus 
aureus ATCC 25923 and Pseudomonas aeruginosa ATCC 27853 were obtained from the American 
Type Culture Collection (Manassas, VA). 
 
5.2.2 S-Nitrosoglutathione (GSNO) synthesis 
The method used to prepare GSNO was the same as that described in Chapter 2. 
5.2.3 Fabrication of NO releasing inserts 
The entire procedure involving GSNO was completed in the absence of direct light.  Silicone 
tubing (ID 0.058″, OD 0.077″) was cut to ~3 cm and sealed at one end using an adhesive glue 
(DOWSIL 3140, MIL-A-46146 RTV Coating) and allowed to dry for 24 h.  Then, 12 ± 0.2 mg of 
a desired dry powder formulation was dispensed into the tubing using a glass funnel pipet.  The 
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dry powder formulations used included (a) 75% GSNO : 25% 30 nm size ZnO nanoparticles; (b) 
25% GSNO : 75% 30 nm size ZnO nanoparticles;  (c) 60% GSNO : 20% 30 nm size ZnO 
nanoparticles : 20% solid polyethylene glycol (MW = 3,350) (PEG); (d) 75% GSNO : 25% fumed 
silica.  Before use, the GSNO was crushed into a fine powder using a mortar and pestle and mixed 
with the other components by vortexing for 1 min to achieve a homogeneous dry powder mixture.  
After filling the tubing with the desired powdered formulation (~12 mg = ~1.8 cm fill length), the 
end that was employed to fill the tubing was cut to achieve ~0.2 cm head space above the fill 
powder.  Lastly, adhesive glue was used to seal the open end and allowed to dry for 24 h.  The 
final length of the inserts are ~ 2.0 cm. 
 
5.2.4 Measuring real-time NO release from inserts 
Nitric oxide release from the NO releasing inserts was measured using a Sievers 
Chemiluminescence Nitric Oxide Analyzer (NOA) 280i (Boulder, CO). The NOA was calibrated 
before via a two-point calibration of N2 gas passed through a NOA zero air filter and a standard of 
44.3 ppm NO in N2 gas. Saline solution (0.9% sodium chloride) was made using 18.2 M Ω 
deionized water using a Milli-Q filter (Milli-q purified water) from EMD Millipore (Billerica, 
MA).  The NOA sample cell was filled with 11 mL of saline solution and the NO releasing insert 
was placed below a floating polypropylene barrier to keep the insert fully submerged at all times.  
The saline solution reservoir was bubbled with N2 gas at a rate of 50 mL/min to allow the NO 
generated from GSNO to escape from the solution and be carried into the NOA by the N2 sweep 
gas. All NOA sample cells were wrapped in aluminum foil to shield the samples from light 
exposure. NO release was continuously monitored for 72 h at room temperature (24°C). 
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5.2.5 In vitro simulated catheter hub antimicrobial assay 
To simulate the hub region of a catheter, 3 cm of silicone tubing (ID 0.125″, OD 0.250″) was 
employed.  A volume of 0.3 mL of overnight grown bacteria cultures (1 × 108 CFU/mL) in 10% 
LB broth was transferred into the simulated hub clamped at one end.  Then, a NO releasing insert 
was placed inside of the simulated hub and the other end clamped shut.  For control samples, no 
NO releasing insert was added.  Each sample was incubated at room temperature (24°C) in the 
dark, for 72 h, on a shaker at low speed.  After 72 h of incubation, 20 µL of bacteria culture liquid 
was retrieved from each simulated hub and 10-fold serially diluted.  Fifty µL of each dilution was 
spread on LB agar plates and incubated at 37°C overnight for colony-forming unit (CFU) counting.  
The simulated hub was also sliced into small pieces and the inside was stained with BacLight 
Live/Dead staining kit in the dark for 15 min to assess the degree of biofilm.  Microscopic images 
were obtained by using a fluorescent microscope with appropriate filter sets (488/520 nm for 
SYTO-9 and 493/636 nm for propidium iodide. 
 
5.2.6 Sterilization studies: Ethylene oxide (EO) vs. hydrogen peroxide (H2O2) 
Nitric oxide releasing inserts (formulation (a)) were prepared as described in Section 5.2.3, 
individually packaged into separate pouches, and sent to the University of Michigan hospital 
sterilization facility for ethylene oxide (EO) or hydrogen peroxide (H2O2) treatment.  For EO 
treatment, the NO releasing inserts undergo a 1 h preconditioning and humidification process 
(54°C, 40-80% humidity), followed by 3 h of exposure to ethylene oxide gas under the same 
temperature and humidity.  Then, a 2 h ethylene oxide gas evacuation process occurs, followed by 
12 h of air washes.  For H2O2 treatment or STERRAD®, the process takes approximately 45 min 
total.  Under vacuum, 59% (nominal) aqueous H2O2 is vaporized to cover the NO releasing inserts.  
 99 
Diffusion of the gaseous H2O2 occurs while the pressure is reduced, forming low-temperature 
H2O2 gas plasma after radio frequency (RF) energy is applied.  The H2O2 gas plasma generated 
sterilizes the NO releasing inserts.  Control NO releasing inserts were prepared as described in 
Section 5.2.3, but not sterilized.  The amount/stability of GSNO within each insert was measured 
by releasing all of the NO from GSNO via shining UV light on them and detecting/quantitating 
the total amount of NO released using a NOA.  Specifically, 2 mL of Milli-q purified water was 
added to an NOA sample cell. After a steady baseline was achieved, a NO releasing insert was cut 
open and the powder filling was transferred into the sample cell using another 2 mL of Milli-q 
purified water.  An additional 1 mL of Milli-q purified water was used to rinse all remaining 
powder on the NOA sample cell walls, down into the bulk solution (total 5 mL of Milli-q purified 
water). The GSNO/ZnO containing solution was bubbled with N2 gas at a rate of 50 mL/min to 
escape from the solution and be carried into the NOA by the N2 sweep gas.  UV light was used to 
irradiate the sample until NO release from GSNO was exhausted, marked by a return to the original 
baseline.  The amount of NO released from each NO releasing insert was directly converted to 
GSNO because the mole ratio is 1:1.  The highest amount of GSNO measured from the three NO 
releasing control inserts (not sterilized) was assumed to be 100% recovery of GSNO; therefore. all 
other samples (sterile and non-sterile) were normalized to this value.  Thus, >100% GSNO 
recovery was possible. 
5.2.7 Stability Study 
Nitric oxide releasing inserts using formulation (a) (75% GSNO : 25% 30 nm size ZnO 
nanoparticles) were prepared.  Three NO releasing inserts were measure for their amount of GSNO 
on Day 0 without any sterilization processes.  On Day 0 the remaining NO releasing inserts were 
sterilized using the H2O2 sterilization method described above.  After sterilization was completed 
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on Day 0, each sterile insert remained in their individual sterilization pouches and were stored in 
a sealed glass jar with desiccant, in the dark, at room temperature (24°C) until further use.  The 
%GSNO recovery from an NO releasing insert on any given day was achieved using the method 
outlined in Section 5.2.6.  Briefly, the NO releasing inserts were cut open and the powder washed 
into a NOA sample cell.  All the NO was exhausted from GSNO using UV light.  The NO was 
quantitated and measured by a NOA.  All recovery values obtained were normalized to the highest 
amount of GSNO obtained from one of the three control NO releasing inserts (not sterilized). 
 
5.2.8 In vitro catheter hub antimicrobial assay 
The catheters utilized for this assay were 28 cm long Permcath™ Pediatric Silicone Chronic Dual 
Lumen Oval Catheters, Covidien/Medtronic (Ref 8815543001, Lot 1611800146).  The clamp on 
the catheter’s hub region was clamped shut and 0.3 mL of overnight grown bacteria cultures (1 × 
108 CFU/mL) in 10% LB broth was added.  A NO releasing insert (pre-sterilized by the H2O2 
sterilization method mentioned above) was inserted inside of the catheter hub and sealed by a cap.  
For control samples, no NO releasing insert was added.  Each catheter was incubated at room 
temperature (24°C) in the dark, for 72 h, on a shaker at low speed.  After 72 h of incubation, 20 
µL of bacteria culture liquid was retrieved from each hub region and 10-fold serially diluted.  Fifty 
µL of each dilution was spread on LB agar plates and incubated at 37°C overnight for colony-
forming unit (CFU) counting. 
 
5.2.9 Sheep studies - general procedure 
This study including animal handling and surgical procedures that were approved by the University 
of Michigan Committee on Use and Care of Animals (24 h fasting and pre-surgical analgesia with 
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Fentanyl transdermal patch 100 µg/h) in accordance with university and federal regulations.  Adult 
sheep weighing 45-50 kg were utilized.  Under general anesthesia, 28 cm long (13 cm cuff to 
proximal tip) Permcath™ Pediatric Silicone Chronic Dual Lumen Oval Catheters, 
Covidien/Medtronic (8815543001) were placed using the Seldinger wire technique in the right and 
left jugular veins (3-5 cm above the subclavian), aiming to place the proximal tip in the RA-SVC 
junction.  Caution was taken not to expose or manipulate the vessels.  Catheters were secured to 
the skin and covered with a sterile dressing.  After catheter placements, the sheep were recovered 
from anesthesia and housed in a barn (non-sterile conditions) for the remainder of the experiment. 
All catheters were capped and filled with 2,000 U heparinized saline solution (2 mL) injected via 
the distal end of the lumen.  The NO releasing inserts used for both sheep studies were made using 
formulation (a) 75% GSNO : 25% 30 nm size ZnO nanoparticles.  The NO releasing inserts were 
attached to male luer lock injection site caps, Qosina (80149), using the same adhesive glue used 
in Section 5.2.3, and allowed to dry for 24 h (Fig. 5.1a).  Each NO releasing insert cap was 
individually packaged and sterilized using the H2O2 sterilization method described previously.  
The sterile NO releasing insert caps were stored at room temperature (24°C) and shielded from 
light until further use. 
Prior to necropsy (day 14), 10,000 U bolus of heparin was given via a cephalic vein angiocath, 
followed by FatalPlus IV injection.  Each catheter was procured using sterile techniques.  The 
external surface of each catheter was sterilized by wiping with a 70% ethanol solution.  One cm 
length sections were cut from each section of catheter as shown in Figure 5.1b.  Each section was 
homogenized in 2 mL of 1 × PBS (10 mM, pH 7.2) in a 15-mL tube using a homogenizer (OMNI 
TH, OMNI International, Kennesaw, GA) at full speed to remove all bacteria/biofilm adhered to 
the inner lumen walls, and the resulting solution was 10-fold serially diluted.  Fifty µL of each 
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dilution was spread on LB agar plates and incubated at 37°C overnight for CFU counting.  
Additionally, >0.5 cm length sections were cut from each section of catheter described in Figure 
5.1b, and the inner lumen surfaces were stained with BacLight Live/Dead staining kit in the dark 
for 15 min.  Microscopic images were obtained by using a fluorescent microscope with appropriate 
filter sets (488/520 nm for SYTO-9 and 493/636 nm for propidium iodide. 
 
Figure 5.1. (a) (top) NO releasing insert cap used in Sheep Study #1 and #2 and (bottom) the 
silicone tubing filled partially with adhesive glue prior to gluing it to cap (pre-glued section is 
inside of cap). (b) Regions of catheter studied in Sheep Study #1 and #2. 
 
5.2.10 Sheep Study #1 
Two adult sheep were studied during Sheep Study #1.  One sheep was designated as control (n = 
4 catheter hubs total, no NO releasing inserts) and the other sheep was designated as experimental 
(n = 4 catheter hubs total, using NO releasing insert caps).  On postoperative days 0, 2, 4, 7, 9, 11, 
and 14, 50 µL of liquid from the hub region of each catheter lumen was taken for CFU counting.  
Then, 3.5 mL of blood was drawn from each lumen, the lumens were then locked with 2,000 U 
heparinized saline solution (2 mL), and both NO releasing insert caps and control caps were 
replaced with new caps, respectively. 
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5.2.11 Sheep Study #2 
Two adult sheep were studied during Sheep Study #2.  Use of a commercially available 
antimicrobial cap with chlorhexidine as the antimicrobial agent was studied and compared to use 
of the new NO releasing insert device.  For one sheep, the catheter implanted in the right jugular 
vein was designated for the commercial chlorhexidine caps and the catheter implanted in the left 
jugular vein was designated for the NO release insert caps.  For the second sheep, the designations 
were reversed such that right jugular vein was designated for the NO release insert caps and the 
catheter implanted in the left jugular vein was designated for the chlorhexidine caps.  In total, for 
chlorhexidine caps there were n = 4 catheter hubs and for the NO releasing insert caps there were 
also n = 4 catheter hubs.  On postoperative days 0, 2, 3, 6, 8, 10, 12, and 14, 50 µL of liquid from 
the hub region of each catheter lumen was taken for CFU counting.  Then, 3.5 mL of blood were 
drawn from each lumen, locked with 2,000 U heparinized saline solution (2 mL), and both NO 
releasing insert caps and chlorhexidine caps were replaced with new caps, respectively. 
 
5.3 Results and Discussion 
5.3.1 Design of NO releasing inserts 
The dimensions of the NO releasing insert were designed based on the hub dimensions of 
commonly used hemodialysis catheters (Fig. 5.2).  S-nitrosoglutathione (GSNO) was chosen as 
the NO donor molecule because it is endogenously produced and fairly stable when stored as a 
powder in the absence of moisture.21, 22  ZnO nanoparticles (30 nm diameter) were chosen to 
enhance the NO release from GSNO.23  Silicone rubber tubing was chosen because the high 
diffusivity of NO through silicone rubber compared to other biomedical grade polymers and its 
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relatively low hardness allows moisture to pass through its walls to initiate NO release from 
GSNO.24 
 
Figure 5.2. Design of NO releasing insert. 
 
5.3.2 Characterizing real-time NO release of NO releasing insert formulations 
The real-time NO release of four different NO releasing insert formulations was evaluated to 
determine each formulation’s NO release characteristics.  Nitric oxide release was measured from 
each NO releasing insert over a 72 h period while submerged in saline solution in the dark at room 
temperature (24°C).  The measurement conditions were as close to “real-world” conditions of 
hemodialysis catheter hubs as possible.  Measuring over a 72 h period was chosen because 
hemodialysis treatments normally occur every 2-3 days, enabling the NO release insert to be 
changed at each dialysis session.  The other conditions were chosen because catheter hubs are 
located outside of the body, opaque, and locked with a saline lock solution. 
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Figure 5.3. Real-time NO flux of inserts prepared with different formulations a-d in the dark at 
24°C over a 72 h period. Data represents the mean ± SD (n = 3). 
 
Four different NO releasing insert formulations were tested for their NO release characteristics 
under real world conditions (Fig. 5.3).  The dry powder NO releasing formulations studied include 
(a) 75% GSNO : 25% 30 nm size ZnO nanoparticles; (b) 25% GSNO : 75% 30 nm size ZnO 
nanoparticles; (c) 60% GSNO : 20% 30 nm size ZnO nanoparticles : 20% solid polyethylene glycol 
(MW = 3,350) (PEG); and (d) 75% GSNO : 25% fumed silica.  Formulation (a) yielded a large 
burst of NO over the first 24 h and tapered off until the 72 h mark was reached (Fig. 5.3).  For 
formulation (b), the percentages of GSNO and ZnO were reversed compared to formulation (a).  
Formulation (b) demonstrated a similar NO release profile compared to formulation (a), however 
the initial burst lasted only 12 h and tapered off significantly afterwards due to the lower amount 
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of GSNO initially present (Fig. 5.3).  In attempt to level/smooth out the NO release profile of 
formulation (a), polyethylene glycol (MW=3,350) (PEG) was added to increase the viscosity of 
the insert’s internal components (GSNO and ZnO).  The addition of PEG should increase the 
internal viscosity upon moisture absorption, imposing a cage effect on the thiyl and NO radical 
pair such that they recombine to form GSNO and slow the rate of NO release.25, 26  The addition 
of PEG led to formulation (c) and still includes GSNO and ZnO.  The expected leveling/smoothing 
effect was achieved, leading to a more consistent NO release rate over 72 h (Fig. 5.3).  To prove 
that ZnO was necessary to enhance NO release in each formulation, fumed silica particles were 
substituted in place of ZnO as an inert agent that does not react with GSNO.  The NO release 
profile of formulation (d) shows minimal NO release over 72 h (Fig. 5.3).  This data definitively 
proves that ZnO is needed to achieve significant NO release from GSNO contained within the 
silicone tubing. 
 
5.3.3 Antimicrobial effects of NO releasing formulations (a-c) inserts in simulated catheter hubs 
Formulations (a-c) displayed unique NO releasing profiles over 72 h.  Therefore, each was tested 
for their bactericidal effects using a “Simulated Hub” antimicrobial experiment.  This experiment 
was designed to mimic the conditions of a real hemodialysis catheter hub.  Silicone tubing with a 
similar inner diameter to that of an actual hemodialysis catheter hub was utilized as the “Simulate 
Hub”.  A detailed description of this study can be found in Section 5.2.5.  Briefly, a given 
concentration of Staphylococcus aureus (S. aureus) in 10% LB broth was put inside of the silicone 
tubing that was sealed at one end.  The NO releasing inserts were place inside of the simulated hub 
and the opposite end closed.  The controls contained no NO releasing insert.  The prepared 
simulated hubs were subjected to real world ambient conditions as stated previously (24°C, dark, 
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72 h, and on a shaker).  After 72 h, the amount of bacteria in the liquid broth was enumerated for 
each sample and the inner lumen wall of the simulated hub was imaged for bacteria/biofilm 
adhered to its surface. 
 
Figure 5.4. Viable cell counts of S. aureus from the liquid broth of simulated catheter hubs after 
72 h of exposure to control (no insert) and NO release inserts with formulations (a), (b), and (c), 
in the dark at 24°C.  The horizontal dashed line represents the LOD (100 CFU/mL) for the assay.  
Data represents the mean ± SD (n = 3). 
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Figure 5.5. Fluorescent microscopic images of S. aureus bacteria/biofilm adhered to the inner 
lumen wall of the simulated hub after exposure to no insert (control) or NO releasing inserts with 
formulations (a-c) for 72 h in the dark at 24°C.  Live/Dead dye stain was used where green = alive 
cells and red = dead cells. 
 
Each NO releasing insert formulation (a-c) killed all of the bacteria present in the liquid broth of 
each simulated hub, leading to a 6.4 log reduction of bacteria compared to control (no NO releasing 
insert) (Fig. 5.4).  This data indicates that formulations (a-c) are capable of killing S. aureus 
bacteria cells in the liquid broth of a simulated catheter hub region.  Fluorescent microscopic 
images were taken of the inner lumen wall of each simulated hub and representative images are 
pictured in Figure 5.5.  The control as well as formulations (b) and (c) displayed evidence of S 
aureus bacteria/biofilm adhered to the inner lumen wall of the simulated hubs (Fig. 5.5).  However, 
formulation (a) showed no evidence of significant S aureus bacteria/biofilm adhesion (Fig. 5.5).  
The data from formulation (a) suggests that having a large burst of NO over the first 24 h is needed 
to prevent biofilm formation.  Therefore, formulation (a), 75% GSNO : 25% 30 nm ZnO 
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nanoparticles, was chosen as the formulation to continue testing because of its excellent 
antimicrobial/anti-biofilm characteristics. 
 
5.3.4 Sterilization and Stability Testing 
Sterilization of the NO releasing inserts would be needed for animal testing.  GSNO naturally 
reacts to release NO in the presence of light, heat, metal ions, and water.21, 22, 25, 27-31 Thus, different 
sterilization methods were tested to see if they had any negative effects on GSNO stability.  Again, 
the NO releasing formulation (a) insert was utilized in these studies.  Two common sterilization 
methods were tested as described in Section 5.2.6 (above), ethylene oxide (EO) gas and hydrogen 
peroxide (H2O2) plasma.  EO sterilization is a traditional sterilization method that takes place at a 
temperature of 54°C and requires several hours to complete.  H2O2 sterilization is a relatively new 
method of sterilization that occurs at a temperature of 40°C and takes ~45 min to complete. 
To test if the sterilization methods effected the stability of GSNO inside of the silicone insert 
tubing, the amount of GSNO (%recovery of GSNO) was measured for NO releasing formulation 
(a) inserts subjected to no sterilization (control), H2O2 sterilization, and EO sterilization.  Since 
each NO releasing insert was made by hand and the amount of GSNO inevitably varies somewhat.  
Thus, the highest amount of GSNO measured from the three NO releasing control inserts (not 
sterilized) was assumed to be 100% recovery of GSNO (Table 5.1).  All other NO releasing inserts 
tested were normalized to this value, and hence >100% recovery values were possible.  The results 
of this study are shown in Table 5.1.  Ultimately, H2O2 sterilization was chosen as the best method 
compared to EO sterilization because of lower standard deviation and quicker turn-around period. 
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Table 5.1. %Recovery of GSNO after no sterilization (control), hydrogen peroxide (H2O2) 
sterilization, or ethylene oxide (EO) sterilization processes.  Values are normalized to the highest 
amount of GSNO recovered from the control (no sterilization) trials.  Data represents the mean ± 
SD (n = 3). 
Control (no sterilization) H2O2 Sterilization EO Sterilization 
98.4 ± 1.6% 100.2 ± 2.4% 95.3 ± 10.1% 
 
After the sterilization method was selected, it was important to test the long-term stability of the 
GSNO inside of the NO releasing inserts.  For this study, NO releasing formulation (a) inserts 
were fabricated and sterilized via H2O2.  However, three NO releasing inserts were not sterilized 
(control) and the amount of GSNO in each insert was determined on Day 0 using the method 
described in Section 5.2.7.  After H2O2 sterilization was completed on Day 0 for the remaining 
inserts, they remained in their individual sterilization pouches and stored in a sealed glass jar with 
desiccant, in the dark, at room temperature (24°C) until further use.  After nearly 2 months of 
storage, the GSNO inside of the NO releasing formulation (a) inserts was found to degrade by an 
average of 4.3% (Fig. 5.6).  Therefore, GSNO is relatively stable when stored dry with ZnO 
nanoparticles inside of the silicone insert devices at room temperature. 
 111 
 
Figure 5.6. %Recovery of GSNO measured on Day 1, 7, and 56 from NO releasing inserts using 
formulation (a), stored in the dark at 24°C after hydrogen peroxide (H2O2) sterilization.  Control 
(no sterilization) NO releasing inserts using formulation (a) were measure for %recovery of GSNO 
on Day 0.  Data represents the mean ± SD (n = 3). 
 
5.3.5 Antimicrobial effects of NO releasing formulation (a) inserts in hemodialysis catheter hubs 
The antimicrobial efficacy of NO releasing formulation (a) inserts in real hemodialysis catheter 
hubs were tested against gram-positive and gram-negative strains, S. aureus, and P. aeruginosa, 
respectively.  A detailed procedure can be found in Section 5.2.8, above.  Briefly, a given 
concentration of bacteria in 10% LB broth was added to a real hemodialysis catheter hub region 
and the hub region was closed at the proximal end of the hub region using the pre-existing clamp.  
H2O2 sterilized NO releasing inserts were then placed inside of the catheter hubs and closed via 
the attached cap.  The control trials contained no NO releasing inserts, just a normal hub cap.  The 
hemodialysis catheter hubs were then subjected to real world conditions as stated previously 
(24°C, dark, 72 h, and on a shaker).  Upon completions of the 72 h study, bacteria counts were 
obtained from the liquid broth inside of the catheter hubs containing the NO releasing formulation 
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(a) inserts versus the controls with no inserts.  This led to a log reduction of 6.6 and 6.7 (compared 
to controls) against S. aureus and P. aeruginosa, respectively.  This data suggests that the NO 
releasing inserts containing formulation (a) are extremely effective at killing both gram-positive 
and gram-negative strains. 
 
5.3.6 Sheep Study #1 
The purpose of Sheep Study #1 was to evaluate the antimicrobial/anti-biofilm performance of the 
NO releasing formulation (a) insert caps versus normal hemodialysis catheter caps by replacing 
each cap every 2-3 d over a 14 d long period.  Detailed procedures for Sheep Study #1 can be 
found in Sections 5.2.9 and 5.2.10.  Briefly, two sheep were studied during Sheep Study #1 with 
one sheep designated as a control (no NO release inserts) and the other sheep experimental (NO 
releasing inserts).  Each sheep had two surgically implanted dual-lumen TDC catheters for a total 
of four catheter hubs each.  The NO releasing formulation (a) inserts were glued to catheter caps 
for convenience (Fig. 5.1a).  During the 14 d study the sheep were housed in a barn at the U of M 
farm.  Control and experimental caps were changed every 2-3 d and blood was drawn through each 
lumen to simulate the average time between dialysis treatments and blood exposure.  Bacteria 
cultures from the liquid in each hub region were taken prior to replacing the caps.  After 14 d, the 
study was terminated and each hemodialysis catheter was evaluated for the amount of 
bacteria/biofilm present on the inside wall of four separate regions of the catheter (Fig. 5.1b). 
The results of the bacteria counts taken from the liquid within the hub region every 2-3 days are 
summarized in Figure 5.7.  On particular days, some unforeseen circumstances prevented 
obtaining a proper liquid sample from each hub region (Day 7, and 11) (Fig. 5.7).  However, the 
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data remains consistent where the control sheep displayed significant bacteria counts after Day 4 
and the experimental sheep (NO releasing insert caps) showed no bacteria on any day, therefore 
reaching the limit of detection (220 CFU/mL) after each day of testing (Fig. 5.7).  A log reduction 
of 3.88 was already observed by Day 4 and increased to 5.42 by Day 14 for experimental sheep 
versus control (Fig 5.7).  This data suggests that the NO releasing formulation (a) insert caps have 
a significant antimicrobial effect against bacteria present in the liquid of the hub region under real 
world conditions.  
 
Figure 5.7. Sheep Study #1 bacteria counts from the hub solution on days 2, 4, 7, 9, 11, and 14 
using normal catheter caps (Control) and NO releasing insert caps (Experimental).  Dashed line is 
the limit of detection (200 CFU/mL).  Log reduction values are given for Experimental vs. Control.  
The number of samples (n = X) is specified for each day.  Data with an error bar represents the 
mean ± SD. 
 
Upon completion of the 14 d study, four regions of each catheter were tested for bacteria/biofilm 
adhered to the inner lumen walls (Fig. 5.1b).  This test was conducted by first sterilizing the outside 
of the catheter, cutting out the specific sections, and using a homogenizer to remove all of the 
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adhered bacteria/biofilm from the inner lumen wall for bacteria enumeration.  The results of this 
study are summarized in Figure 5.8.  For the control catheters, all four regions of the catheters had 
a significant amount of bacteria/biofilm present.  For catheters with the experimental NO releasing 
insert caps, no bacteria were detected in any of the four regions (Fig. 5.8).  Interestingly, 
bacteria/biofilm prevention was observed in all regions of the catheter and not just the hub region 
(where the NO is locally released).  This data quantitatively suggests that bacteria can migrate to 
the proximal regions of the catheter from the hub region and that the NO releasing formulation (a) 
insert caps have significant antibacterial/anti-biofilm potential throughout all regions of a catheter 
during a real world situation. 
 
Figure 5.8. Sheep Study #1 bacteria/biofilm adhered to the inner lumen wall of the hub region, 
tunneled region, distal intravascular region, and proximal tip of catheters using normal catheter 
caps (Control) and NO releasing insert caps (Experimental).  Dashed line is the limit of detection 
(400 CFU/segment).  Log reduction values are given for Experimental vs. Control.  The number 
of samples (n = X) are specified for each section of catheter.  Data with an error bar represents the 
mean ± SD. 
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Fluorescent microscopic images were taken of the inner lumen walls of each region of the catheters 
using Live/Dead dye stain upon termination of the study (Fig. 5.9).  Experimental catheters (NO 
releasing insert caps) displayed minimal to no bacteria adhered to the inner lumen walls in all 
regions (Fig. 5.9).  The control catheters displayed significant bacteria/biofilm adhesion in all four 
regions (Fig. 5.9).  This data qualitatively suggests that the NO releasing formulation (a) insert cap 
prevents bacteria/biofilm formation in each catheter region during a real world study. 
 
Figure 5.9. Sheep Study #1 fluorescent microscopic images of bacteria/biofilm adhered to the 
inner lumen wall of the (1) hub region, (2) tunneled region, (3) distal intravascular region, and (4) 
proximal tip of catheters using normal catheter caps (Control) and NO releasing insert caps 
(Experimental).  Live/Dead dye stain was used where green = alive cells and red = dead cells. 
 
5.3.7 Sheep Study #2 
The purpose of Sheep Study #2 was to compare the antimicrobial/anti-biofilm performance the 
NO releasing formulation (a) insert cap versus a commercially available antimicrobial cap that 
utilizes chlorhexidine as the antimicrobial agent.  For both type of inserts, each cap was replaced 
every 2-3 d over a 14 d long period.  Detailed procedures for Sheep Study #2 can be found in 
sections 5.2.9 and 5.2.11.  Briefly, two sheep were studied and for one sheep the dual-lumen 
catheter was surgically implanted in the right jugular vein and it was designated for use with the 
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chlorhexidine caps, while the dual-lumen catheter implanted in the left jugular vein was designated 
for the NO release insert caps.  For the second sheep, the cap designations were reversed to the 
opposite jugular veins.  Both sheep were housed in a barn during the 14 d study. The same 
procedures were performed in Sheep Study #1 as were performed in Sheep Study #2.  
Chlorhexidine and experimental NO release caps were changed every 2-3 d and blood was drawn 
through each lumen to simulate the average time between dialysis treatments and blood exposure.  
Bacteria cultures were taken from the liquid in each hub region prior to replacing the caps.  After 
the study was terminated on Day 14, each hemodialysis catheter was evaluated for the amount of 
bacteria/biofilm present in four different regions of the catheter (Fig. 5.1b). 
The bacteria counts taken from the liquid of the hub region every 2-3 days yielded no bacteria 
detected on any day for both chlorhexidine and experimental catheters.  This data suggests that 
chlorhexidine caps display significant antimicrobial effects against bacteria present in the liquid 
phase of the hub region.  This data also confirms the results obtained in Sheep Study #1 for the 
NO releasing formulation (a) insert cap because the same results (no bacteria detected on any day) 
were obtained in Sheep Study #2. 
After the 14 d study was completed, four regions of each catheter were tested for bacteria/biofilm 
adhered to the inner lumen walls (Fig. 5.1b).  The outside of each catheter was sterilized, then the 
specific sections of the catheter were cut out and bacteria/biofilm adhered to the inner lumen walls 
were removed using a homogenizer for bacteria enumeration.  The results of this study are 
summarized in Figure 5.10.  For the experimental catheters, minimal bacteria were detected in the 
hub and tunneled regions and no bacteria were detected in the distal intravascular region and 
proximal tip (Fig. 5.10).  For the chlorhexidine catheters, bacteria/biofilm was detected in all four 
regions (Fig. 5.10).  The tunneled region of the catheter had the largest log reduction of bacteria 
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(3.82) for the experimental versus chlorhexidine catheters (Fig. 5.10).  Overall, this data suggests 
that the NO releasing formulation (a) insert caps are much more capable at preventing 
bacteria/biofilm formation in all four regions of a hemodialysis catheter compared to commercially 
available chlorhexidine caps. 
 
Figure 5.10. Sheep Study #2 bacteria/biofilm adhered to the inner lumen wall of the hub region, 
tunneled region, distal intravascular region, and proximal tip of catheters using normal catheter 
caps (Control) and NO releasing insert caps (Experimental).  Dashed line is the limit of detection 
(400 CFU/segment).  Log reduction values are given for Experimental vs. Control.  The number 
of samples (n = X) are specified for each section of catheter.  Data with an error bar represents the 
mean ± SD. 
 
Fluorescent microscopic images were taken of the inner lumen walls of each region of the catheters 
using Live/Dead dye stain after study termination (Fig. 5.11).  The chlorhexidine catheters 
displayed significant bacteria/biofilm adhered to the inner lumen wall of the tunneled region, 
which corresponds to the elevated bacteria/biofilm counts obtained from the tunneled region (Fig. 
5.10, Fig. 5.11).  The experimental catheters (NO releasing insert caps) displayed minimal to no 
bacteria adhered to the inner lumen walls of all four regions (Fig. 5.11).  This data indicates that 
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the NO releasing formulation (a) insert cap prevents more bacteria/biofilm formation in each 
catheter region compared to the commercially available chlorhexidine cap. 
 
Figure 5.11. Sheep Study #2 fluorescent microscopic images of bacteria/biofilm adhered to the 
inner lumen wall of the (1) hub region, (2) tunneled region, (3) distal intravascular region, and (4) 
proximal tip of catheters using chlorhexidine caps (Chlorhexidine) and NO releasing insert caps 
(Experimental).  Live/Dead dye stain was used where green = alive cells and red = dead cells. 
 
5.4 Conclusion 
The real-time NO releasing characteristics of four different NO releasing insert formulations were 
determined under real world conditions (24°C, dark, 72 h, submerged in saline).  Formulation (a) 
demonstrated high initial NO flux levels compared to the other formulations.  Formulation (b) 
demonstrated similar characteristics to formulation (a), however the NO fluxes were significantly 
lower.  Formulation (c) contained PEG to smooth/level out the NO flux over the 72 h period.  
Formulation (d) contained no ZnO and displayed minimal NO release, therefore further proving 
that ZnO is needed in the formulation to display significant NO release capability.  Testing the 
antimicrobial/anti-biofilm efficacy of formulations (a-c) using an simulated catheter hub assay 
against S. aureus revealed that formulation (a) was the best at preventing biofilm formation 
because of the large initial burst of NO that formulation (a) provides.  Testing the %recovery of 
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GSNO from inside of the NO releasing formulation (a) inserts after different sterilization 
techniques revealed that minimal to no GSNO decomposition occurs during the H2O2 sterilization 
process.  Thus, due to minimal GSNO decomposition and faster sample turn-around time, H2O2 
sterilization was chosen as the main sterilization procedure.  A preliminary shelf-life stability study 
of H2O2 sterilized NO releasing formulation (a) inserts showed minimal degradation of GSNO 
(4.3%) after 56 d of being stored at 24°C, in the dark, and in the presence of desiccant.  It was also 
discovered that H2O2 sterilized NO releasing formulation (a) inserts are highly effective at killing 
both gram-negative (P. aeruginosa) and gram-positive (S. aureus) strains (6.7 and 6.6 log 
reduction, respectively) from the liquid present in actual catheter hubs under real world conditions 
(24°C, dark, 72 h).  Sheep Study #1 revealed that the NO releasing formulation (a) insert caps are 
highly effective at killing/preventing bacteria and biofilm formation at all regions of a 
hemodialysis catheter compared to the control that had a normal catheter cap.  Sheep Study #2 
confirmed the results of Sheep Study #1 for the NO releasing formulation (a) insert cap.  Sheep 
Study #2 also revealed that the NO releasing formulation (a) insert cap prevents bacteria growth 
and biofilm formation better than a commercially available antimicrobial cap that utilizes 
chlorhexidine.  Overall, this research has clearly demonstrated that the NO releasing formulation 
(a) insert cap demonstrates significant antimicrobial/anti-biofilm effects and should be useful in 
significantly decreasing the risk of infection for dialysis patients that have TDCs in place. 
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Chapter 6 Conclusions and Future Directions  
 
6.1 Conclusions 
This dissertation research has focused on examining the characteristics and antimicrobial 
properties of newly devised NO releasing creams and devices.  Furthermore, a novel method for 
enhancing NO release from GSNO using ZnO nanoparticles was introduced and investigated.  
Overall, each project had the goal of preventing/treating infections in the biomedical field.  
Therefore, practicality of each application led to the heavy utilization of a natural/endogenous NO 
donor, GSNO. 
In Chapter 2, enhanced, long-term stability of GSNO when stored in Vaseline was observed.  The 
enhanced stability was attributed to the dry storage conditions as well as the hydrophobicity, and 
high viscosity of Vaseline.  Four secondary creams were evaluated for their ability to proliferate 
NO from GSNO stored in Vaseline.  A commercially available ZnO-containing cream yielded the 
most NO released during the initial 6 h test period at both 24°C and 34°C.  The NO release kinetics 
using the commercial ZnO-containing cream to initiate NO release from GSNO in Vaseline 
displayed first-order NO release kinetics.  The observed rate constants for NO releasing 
formulations with 3, 6, and 9 wt% GSNO revealed that the rate of NO release was independent of 
GSNO concentration.  Lastly, measuring NO release from the GSNO-Vaseline-ZnO cream in the 
presence of ambient light versus dark, revealed no significant impact on the rate of NO release. 
Chapter 3 evaluated the antimicrobial effects of the NO releasing two-part creams introduced in 
Chapter 2.  The 3, 6, and 9 wt% GSNO in Vaseline/ZnO cream were tested against S. aureus, S. 
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epidermidis, and P. aeruginosa using an indirect application assay, where there was a thin silicone 
membrane between the NO releasing cream and the bacteria grown on LB agar plates.  Overall, 
the more NO produced yielded a greater killing effect for each bacteria strain.  The various NO 
releasing creams were also tested against the same bacteria using a direct application assay on pig 
skin.  The killing effect on both types of surface matrices (pig skin and agar gels) was similar.  
Compared to a commercially available antibiotic-containing cream (Neosporin), each NO 
releasing cream formulation was able to exceed or match the killing effect achieved by Neosporin 
for all three bacteria strains examined.  The NO releasing cream was combined with an antibiotic-
containing cream and tested using direct application on pig skin of pre-grown S. aureus, S. 
epidermidis, and P. aeruginosa biofilms.  The NO + antibiotic cream formulation proved most 
effective against the P. aeruginosa biofilm because the antibiotics present are known to be highly 
potent against gram-negative bacteria strains.  The relative pH of the NO releasing formulation 
was determined to be quite acidic.  Therefore, NaHCO3 was added to create a more neutral pH NO 
releasing cream to prevent any negative consequences (e.g., burning sensation on skin, etc.) of the 
acidic pH of the original formulation.  First-order NO release kinetics were observed for the new 
neutral pH NO releasing cream compared to the kinetics of the acidic pH NO releasing cream 
evaluated in Chapter 2.  The results indicated that the addition of NaHCO3 has no major influence 
on the observed NO release kinetics.  The neutral pH NO releasing cream was tested using the 
direct application assay on pig skin against S. aureus, S. epidermidis, and P. aeruginosa.  This test 
revealed that the relative acidity of the initial NO releasing creams tested had no major contribution 
to the killing effects observed. 
In Chapter 4, it was determined that Zn2+ ion, potentially formed from slight dissolution of ZnO or 
present as impurities in ZnO preparations, have little or no effect on enhancing NO release from 
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GSNO.  A component study was performed that tested all the compounds present in the 
commercial ZnO cream for their potential to enhance NO release from GSNO.  ZnO nanoparticles 
were found to be the primary component responsible for enhancing NO release from GSNO.  NO 
release kinetics from GSNO in the presence of different sized ZnO nanoparticles revealed zero-
order NO release kinetics during the first 10 h of reaction in the dark, at 24°C, and under neutral 
pH conditions.  Also, it was discovered that the NO release rate does increase with decreasing ZnO 
nanoparticle size, but not in a directly proportional manner.  The NO release profiles observed 
using Tris-HCl buffer versus Tris-H3PO4 buffer in the presence of GSNO and ZnO nanoparticles 
revealed that GSNO needs uninhibited access to the surface of ZnO to enhance NO release. Indeed, 
it appears that some equilibrium form of phosphate ions may interact with the surface and reduce 
access of the GSNO species from reaching the surface to react with the ZnO.  Lastly, XPS was 
used to analyze the surface of ZnO nanoparticles after exposure to GSNO.  This experiment 
detected no trace of thiol attachment or Zn-S bond formation. 
Chapter 6 introduced a NO releasing insert device that disinfects the hub region of tunnel dialysis 
catheters (TDCs).  The real-time NO release characteristics of four different NO releasing 
formulations (a-d) were evaluated using real world conditions for a TDC (24°C, dark, 72 h, and 
submerged in saline).  These tests revealed that ZnO must be present to enhance NO release from 
GSNO.  Testing the antimicrobial capabilities of formulations (a-c) using a simulated hub assay 
revealed that each formulation was capable of killing all of the S. aureus bacteria present in the 
liquid broth of a simulated hub after 72 h of exposure at 24°C.  S. aureus bacteria/biofilm adhered 
to the inner lumen wall of the simulated hub were evaluated using a Live/Dead dye stain and taking 
fluorescent microscopic images upon completion of the 72 h study.  The fluorescent microscopic 
images revealed that the characteristic of a large burst of NO during the first 24 h of incubation 
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displayed by formulation (a) was necessary to kill all bacteria, such that none adhered to the inner 
lumen wall as biofilm.  Two sterilization techniques were evaluated to see which method 
decomposed the most GSNO during the respective procedures.  It was determined that sterilization 
via H2O2 gas resulted in minimal GSNO decomposition.  A short term shelf-life stability study 
was completed for the NO releasing formulation (a) inserts after being H2O2 sterilized and stored 
in the dark at 24°C, and in the presence of desiccant.  After 56 d, the GSNO present in the NO 
releasing inserts only degraded by 4.3% on average.  The H2O2 sterilized NO releasing formulation 
(a) inserts were subjected to another antimicrobial test using real catheter hubs inoculated with a 
solution containing either S. aureus (gram-positive) or P. aeruginosa (gram-negative) bacteria.  
The test resulted in a 6.6 and 6.7 log unit reduction from the liquid present in actual catheter hubs 
under real world conditions (24°C, dark, 72 h) for S. aureus and P. aeruginosa, respectively.  The 
14 d long Sheep Study #1 tests revealed that the NO releasing formulation (a) insert caps are 
effective at killing a preventing bacteria and biofilm growth in all regions of a TDC versus the 
control of a normal catheter cap.  Sheep Study #2 tested the NO releasing formulation (a) insert 
caps against commercially available antimicrobial caps that utilize chlorhexidine as the 
antimicrobial agent.  Both NO release caps and commercial caps kill all bacteria present in the 
liquid phase within the hub region during the 14 d study.  However, the NO releasing insert caps 
were also able to prevent biofilm growth on the inner lumen of the entire catheter to a much greater 
extent than the commercial chlorhexidine coated cap. 
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6.2 Future Directions 
6.2.1 Goals for future directions 
To continue the research reported in this thesis, there are a few important goals.  The first goal is 
to assess if the NO releasing cream is safe/non-toxic to human skin.  Hence, the safety of the NO 
releasing cream needs to be evaluated using a living animal model.  The second goal is to 
understand the fundamentals of the mechanism of the reaction between GSNO and ZnO 
nanoparticles.  That is exactly how does the GSNO interact with the ZnO surface that leads to 
acceleration of the NO release from this S-nitrosothiol species.  The third goal is to ensure that 
none of the components present inside of the NO releasing insert, leach out of the insert while 
being used inside of a catheter hub.  Leaching studies will evaluate the relative safety of using the 
NO releasing inserts in humans.  Detailed suggestions for studies to examine these areas are 
described below. 
6.2.2 Cytotoxicity study of NO releasing two-part cream via live pig models 
It is necessary to understand whether the NO produced locally by the GSNO-based NO release 
creams developed in this thesis work exhibits any toxicity toward live skin cells and whether the 
creams have other biomedical applications (beyond treating dermal infections, etc.).  Therefore, a 
project is now being planned to collaborate with Dr. Raimon Duran-Struuck, Assistant Professor 
and Director of Laboratory Animal Medicine Residency Program at the University of 
Pennsylvania.  The overall goal of this project is to prevent/reduce the effects of graft-versus-host 
disease (GVHD) after hematopoietic cell transplantations (HCT).  GVHD is a common problem 
caused by HTC, leaving patients with high risk of infection and potential long term side effects.1, 
2  GVHD targets organs such as the liver, gastrointestinal tract, and skin, with the most common 
target being the skin.3  Acute GVHD is an immunologically mediated process where donor T cells 
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attack host tissue, commonly causing eczema, rosacea, and psoriasis.4, 5  Past preventions strategies 
include blocking inflammatory cascades that activate donor T cells, however these therapies are 
not fully effective because the immunosuppression drugs also non-selectively inhibit host 
regulatory T cells (Tregs) that are important for controlling GVHD.6 
It has been hypothesized that there are potential interactions between the skin microbiome and the 
immune system that likely influences the development of skin-GVHD post HCT.  Chronic 
inflammatory and autoimmune disorders such as atopic dermatitis (AD), rosacea and psoriasis 
have been linked to commensal microbiota in skin.5, 7, 8  Skin bacteria can act as endogenous 
adjuvants, and can shape T cell responses through their capacity to modulate the local milieu (i.e. 
IL-1 production) and by promoting the overgrowth of S. aureus, thereby inducing flares in AD.8, 9  
Recent studies have shown that ultraviolet (UV) therapy can modify the skin microflora to improve 
sclerotic skin conditions.10  The mechanism of the antimicrobial effects from UV irradiation is not 
clear, however the skin contains large stores of nitric oxide (NO) that release upon UV irradiation 
(likely, in part, from endogenous RSNO species).11  NO is a potent antimicrobial, anti-biofilm, and 
antifungal agent that is naturally produced endogenously by the enzyme nitric oxide synthase 
(NOS) and is responsible for several regulatory body functions.12-18  Therefore, a hypothesis is that 
applying the NO releasing two-part cream developed in Chapters 2 and 3 may decrease the 
bacterial burden fueling GVHD. 
Three pigs will receive an allogenic bone marrow transplant (BMT) for the induction of GVHD.  
One week prior to transplant, the NO releasing cream will be applied near the surgical area.  After 
transplant, the NO releasing cream will be applied daily for one month.  Three additional pigs will 
receive daily treatments of the NO releasing cream without receiving a BMT (GVHD-free control) 
for one month as well.  Blood immunophenotype, microbiome, and skin biopsy samples will be 
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analyzed weekly.  Histology samples will be taken weekly and will be assessed for any cytotoxic 
effects the NO releasing creams (seen on control/GVHD-free pigs). 
 
6.2.3 Determination of mechanism between GSNO and ZnO nanoparticles 
The experiments performed in Chapter 4 established that ZnO nanoparticles were the responsible 
component present in the ZnO commercial cream for the enhanced NO release observed from 
GSNO incorporated within Vaseline.  Further studies suggested that GSNO needs uninhibited 
access to the surface of the ZnO particles and that the ZnO surface is not modified with thiol 
moieties post reaction with GSNO.  The mechanism by which ZnO reacts with GSNO to enhance 
NO release is unknown.  However, a hypothesized mechanism involves oxygen vacancies present 
on the ZnO nanoparticle surface (Fig. 6.1). 
 
Figure 6.1. Proposed scheme for the mechanism by which ZnO nanoparticles react with GSNO to 
enhance NO release.  Blue dots represent electrons trapped in oxygen vacancies on the surface of 
ZnO.  The red positive sign represents a net positive area that remains in the oxygen vacancy after 
the trapped electron facilitates a reduction reaction with GSNO. 
 
The rationale behind this hypothesized mechanism is as follows.  ZnO nanoparticles can contain 
defects known as singly ionized oxygen vacancies (i.e. oxygen vacancy with one electron).19, 20  
Prasanna et al. demonstrated that a superoxide radical can form by atmospheric oxygen reacting 
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with an electron from the surface of ZnO while in the dark (Fig. 6.2).19  Therefore, the hypothesis 
that GSNO could react with an electron from the surface of ZnO while in the dark is possible.  
After the electron is removed from the ZnO surface, a hole is generated with a net positive charge.  
An oxidation reaction could then occur between the GS- and the hole, yielding GS radical and 
subsequently glutathione disulfide (GSSG). 
 
Figure 6.2. Image depicting the production of superoxide radicals via atmospheric oxygen reacting 
with an electron from the surface of ZnO (oxygen vacancy).19 
 
One method for detecting oxygen vacancies on the surface of ZnO involves using X-ray 
photoelectron spectroscopy (XPS).  This technique is described in detail by Zhang et al.20  Briefly, 
analyzing the O 1s spectra of ZnO nanoparticles normally yields a signal at ~530.1 eV relating to 
oxygen present in the ZnO crystal lattice (OL) and a signal at ~532.1 eV relating to surface 
hydroxyl groups bound to oxygen vacancies/defects (OH).
19, 20  Then, the atomic ratio of OL to OH 
can be calculated and related to the concentration of oxygen vacancies present, where a higher 
atomic ratio corresponds to a higher concentration of oxygen vacancies.19, 20  Thus, analyzing the 
different sized ZnO nanoparticles used in Chapter 4 (30, 50, and 200 nm in diameter) via XPS and 
calculating their corresponding atomic ratios between OL and OH may determine if the relative 
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concentration of oxygen vacancies relates to the rate of NO release each size of ZnO nanoparticle 
causes. 
Another method for detecting oxygen vacancies on the surface of ZnO involves using electron 
paramagnetic resonance (EPR).  This technique is described in detailed by the same authors Zhang 
et al.20  Briefly, EPR has been used to observe the electron spin state and the structure on the 
surface of ZnO nanoparticles.20  Specifically, ZnO nanoparticles naturally produce an EPR signal 
at a g-factor of ~1.9568 (g-factor is a proportionality factor used to describe the electron spin 
state).20  However, an EPR signal at a g-factor of ~2.0035 corresponds to an unpaired electron 
trapped in an oxygen vacancy site.20-23  A stronger signal at g-factor 2.0035 will correspond to a 
higher concentration of oxygen vacancies present on the surface of ZnO.20  Analyzing the different 
sized ZnO nanoparticles used in Chapter 4 (30, 50, and 200 nm diameter) could indicate any 
difference in concentration of oxygen vacancies present and any correlations to the rate of NO 
release from GSNO cause by the different sized ZnO nanoparticles, may be determined. 
Another experiment that could help prove or disprove the mechanism proposed in Figure 6.1 is 
determination of the products of the reaction between GSNO and ZnO nanoparticles.  Currently, 
the proposed product is glutathione disulfide (GSSG).  Therefore, a long term experiment could 
be performed where the consumptions of GSNO and the formation of GSSG are monitored via 
nuclear magnetic resonance (NMR) spectroscopy and high-performance liquid chromatography-
mass spectrometry (HPLC-MS).  Each reaction will have a known amount of GSNO and ZnO 
nanoparticles in a reaction vessel and be performed at room temperature (24°C), in the dark, under 
constant stirring via a stir bar and bubbling with N2 gas.  One reaction will be performed in the 
presence of D2O for NMR experiments and the other reaction performed in purified deionized 
water for HPLC-MS experiments.  Each reaction will be monitored for GSNO consumption and 
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GSSG formation daily via NMR and HPLC-MS until the full reaction is completed (no more 
detection of GSNO). 
 
6.2.4 Leaching study for NO releasing insert 
There is probable cause to determine if any component from inside of the NO releasing insert 
devices (GSNO/ZnO) described in Chapter 5 are able to leach out from the silicone tubing.  After 
construction of a NO releasing insert is complete (GSNO/ZnO dry powder inside of a silicone 
tube, securely sealed at both ends using a silicone adhesive glue) the components inside of the 
insert should not be able to leach out of the interior of the insert when soaked in solution.  A 
leaching study can be performed to determine if this hypothesis is true. 
Preliminary data was collected for the detection of zinc in the leaching solutions using inductively 
coupled plasma mass spectrometry (ICP-MS).  Two scenarios pictured in Figure 6.3b, were tested.  
The NO releasing formulation (a) inserts/caps were prepared as described in Chapter 5, Sections 
5.2.3 and 5.2.9.  The leaching study was performed by soaking the insert samples in a defined 
volume (10 mL) of purified deionized water.  Purified deionized water was used because the ICP-
MS could be damaged by the high salt concentration in saline solution.  Control insert samples 
were only the silicone tubing and the glue adhesive with no GSNO or ZnO present.  After 24 h of 
soaking, the insert samples were removed, thoroughly washed, dried using a Kimwipe, and 
submerged again in fresh purified deionized water (1st 24 h samples in Fig. 6.3a).  This process 
was repeated the following two days.  After collection of the solutions, the concentration of zinc 
content in each was measured using ICP-MS.  The results of this preliminary leaching study are 
found in Figure 6.3a.  
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Figure 6.3. Preliminary leaching study from the NO releasing inserts using ICP-MS. (a) 
Concentration of Zn (ppb) detected for Control (only silicone tubing and glue, no GSNO and no 
ZnO present), NO insert under the condition defined as “entire insert soaked”, and NO insert under 
the condition defined as “partial insert soaked” after 24 h soaking increments in purified deionized 
water for a total of 72 h.  Data represents the mean ± SD (n = 3). (b) Conditions defined for the 
leaching test, defined as entire insert soaked or partial insert soaked. 
 
The concentration of zinc detected for the two different soaking conditions of the NO releasing 
inserts and NO releasing insert caps after the first 24 h are extremely different (1394.3 ppb vs. 76.8 
ppb, respectively) (Fig. 6.3a).  The difference between the two soaking methods was that the end 
of the silicone tube that was sealed second (right after filling the silicone tube with the GSNO/ZnO 
powder), was directly exposed to solution when the entire NO releasing insert was soaked.  In 
contrast, the other scenario was where this end of the silicone tubing was inside of the cap and not 
exposed to solution.  Thus, a conclusion can be made that ZnO is able to creep out of the end of 
the silicone tubing that is sealed on the second end because that end of the tubing is directly 
exposed to the ZnO before sealing, whereas the other end of the silicone tubing is pre-sealed and 
dried before any exposure to ZnO (creating a more solid seal).  The large error bar for the NO 
releasing insert that was entirely soaked, indirectly demonstrates this phenomenon because the 
amount of ZnO that could be close to the edge of the second sealed end could vary immensely 
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because the inserts are made by hand (Fig 6.3a).  Overall, this data definitely proves that zinc is 
not leaching out from the walls of the silicone tubing of the NO releasing insert. 
Further studies need to be completed to determine if GSNO or related compounds (GSH, GSSG) 
leach out from the silicone tubing when soaked in solution.  For the detection/quantification of 
GSNO the same leaching study can be performed as described above and the liquid samples can 
be analyzed by high-performance liquid chromatography-mass spectrometry (HPLC-MS). 
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